Page last updated: 2024-10-17

salicylic acid and Pruritus

salicylic acid has been researched along with Pruritus in 66 studies

Scalp: The outer covering of the calvaria. It is composed of several layers: SKIN; subcutaneous connective tissue; the occipitofrontal muscle which includes the tendinous galea aponeurotica; loose connective tissue; and the pericranium (the PERIOSTEUM of the SKULL).

Pruritus: An intense itching sensation that produces the urge to rub or scratch the skin to obtain relief.

Research Excerpts

ExcerptRelevanceReference
"A proprietary topical blend of salicylic acid and highly purified sandalwood oil from Australia was used in this open-label study in adolescents and adults with mild to moderate facial acne."9.16Single-center, open-label study of a proprietary topical 0.5% salicylic acid-based treatment regimen containing sandalwood oil in adolescents and adults with mild to moderate acne. ( Levenson, C; Moy, RL; Rock, JA; So, JJ, 2012)
"To compare lipohydroxyacid and salicylic acid peels in subjects with comedonal acne."9.15Randomized trial comparing a chemical peel containing a lipophilic hydroxy acid derivative of salicylic acid with a salicylic acid peel in subjects with comedonal acne. ( Bissonnette, R; Hamzavi, I; Levesque, A; Rougier, A; Seite, S, 2011)
"Clinical trials have demonstrated the efficacy of fixed-dose combination calcipotriol/betamethasone (Cal/BD) aerosol foam for the treatment of patients with scalp psoriasis."8.31Prospective Observational Evaluation of Fixed Combination Calcipotriol/Betamethasone Aerosol Foam (Enstilar®) in the Management of Psoriasis with Scalp Involvement in Everyday Clinical Practice (the CAPITIS Study). ( Hutt, HJ; Staubach, P; von Kiedrowski, R; Wurzer, E, 2023)
"Due to the actives urea, lactate, polidocanol, and the anti-inflammatory licochalcone A, the new scalp tonic exhibited excellent performance in alleviating scalp dryness, itching, microinflammation, and in normalizing disturbances of scalp lipids."5.17Efficacy of a new tonic containing urea, lactate, polidocanol, and glycyrrhiza inflata root extract in the treatment of a dry, itchy, and subclinically inflamed scalp. ( Baufeld, C; Drescher, P; Filbry, A; Höpfner, S; Lüttke, J; Max, H; Mess, A; Oltrogge, B; Rippke, F; Schweiger, D, 2013)
"A proprietary topical blend of salicylic acid and highly purified sandalwood oil from Australia was used in this open-label study in adolescents and adults with mild to moderate facial acne."5.16Single-center, open-label study of a proprietary topical 0.5% salicylic acid-based treatment regimen containing sandalwood oil in adolescents and adults with mild to moderate acne. ( Levenson, C; Moy, RL; Rock, JA; So, JJ, 2012)
"To compare lipohydroxyacid and salicylic acid peels in subjects with comedonal acne."5.15Randomized trial comparing a chemical peel containing a lipophilic hydroxy acid derivative of salicylic acid with a salicylic acid peel in subjects with comedonal acne. ( Bissonnette, R; Hamzavi, I; Levesque, A; Rougier, A; Seite, S, 2011)
"Clinical trials have demonstrated the efficacy of fixed-dose combination calcipotriol/betamethasone (Cal/BD) aerosol foam for the treatment of patients with scalp psoriasis."4.31Prospective Observational Evaluation of Fixed Combination Calcipotriol/Betamethasone Aerosol Foam (Enstilar®) in the Management of Psoriasis with Scalp Involvement in Everyday Clinical Practice (the CAPITIS Study). ( Hutt, HJ; Staubach, P; von Kiedrowski, R; Wurzer, E, 2023)
"Despite the high prevalence of pruritus, scalp skin is less sensitive to histamine-induced experimental itching."3.71Sensitivity of human scalp skin to pruritic stimuli investigated by intradermal microdialysis in vivo. ( McGlone, F; Rukwied, R; Schmelz, M; Zeck, S, 2002)
" Adverse events were predominantly mild or moderate."2.84Safety and Efficacy of Escalating Doses of Ingenol Mebutate for Field Treatment of Actinic Keratosis on the Full Face, Full Balding Scalp, or Chest. ( Berman, B; Bukhalo, M; Hanke, CW; Pariser, DM; Siegel, D; Skov, T; Swanson, N; Villumsen, J; Weiss, JS, 2017)
"Scalp dysesthesia is an abnormal sensation of the scalp in the absence of cutaneous disease."2.82Scalp dysesthesia: a neuropathic phenomenon. ( Ju, T; Vander Does, A; Yosipovitch, G, 2022)
" Safety was assessed according to the evaluations of trained observers and adverse event (AE) reports."2.78Assessment of the safety and efficacy of three concentrations of topical ivermectin lotion as a treatment for head lice infestation. ( Bell, M; Meinking, TL; Mertz-Rivera, K; Villar, ME, 2013)
"Histamine levels were assessed in two groups of subjects with dandruff before and after 3 weeks of treatment with a commercial potentiated zinc pyrithione shampoo."2.76Scalp stratum corneum histamine levels: novel sampling method reveals association with itch resolution in dandruff/seborrhoeic dermatitis treatment. ( Fieno, A; Filloon, T; Kerr, K; Mills, KJ; Schwartz, JR; Szepietowski, JC; Wehmeyer, K, 2011)
"Scalp pruritus is a frequent problem encountered in dermatological practice."2.61Scalp Pruritus: Review of the Pathogenesis, Diagnosis, and Management. ( Rattanakaemakorn, P; Suchonwanit, P, 2019)
"There are multiple types of dysesthesias depending on the body location and the nerves involved."2.53Neurocutaneous disease: Neurocutaneous dysesthesias. ( Cole, E; Fernandez, KH; Shumway, NK, 2016)
"Scalp pruritus is a common complaint that is considered a diagnostically and therapeutically challenging situation."2.47The itchy scalp--scratching for an explanation. ( Bin Saif, GA; Ericson, ME; Yosipovitch, G, 2011)
"Scalp involvement and hair loss have not been reported among cutaneous changes associated with collagen VI mutations."1.91Alopecia in Patients with Collagen VI-Related Myopathies: A Novel/Unrecognized Scalp Phenotype. ( Baraldi, C; Bruni, F; Cedirian, S; Di Martino, A; Merlini, L; Misciali, C; Pampaloni, F; Piraccini, BM; Quadrelli, F; Sabatelli, P; Starace, M, 2023)
"Pruritus is the sensation of itching; it can be caused by dermatologic and systemic conditions."1.72Pruritus: Diagnosis and Management. ( Honeycutt, JD; Rupert, J, 2022)
"Scalp pruritus is a common skin problem that remains therapeutic challenge."1.72Microbiota profiling on itchy scalp with undetermined origin. ( Chang, X; Li, X; Shi, Y; Yan, H; Yang, F; Zhang, M; Zhang, Y, 2022)
"Scalp dysesthesia is characterised by abnormal cutaneous sensations such as burning, stinging or itching of the scalp in the absence of objective dermatological findings."1.48Treatment of scalp dysesthesia utilising simple exercises and stretches: A pilot study. ( Chan, J; Laidler, NK, 2018)
" In conclusion, superficial cryotherapy is an effective and safe therapeutic modality for AA."1.46Efficacy and safety of superficial cryotherapy for alopecia areata: A retrospective, comprehensive review of 353 cases over 22 years. ( Jun, M; Lee, NR; Lee, WS, 2017)
"Eighteen patients with seborrheic dermatitis or psoriasis vulgaris scalp eruptions were instructed in proper techniques of daily hair washing, rinsing, and shampooing, which they underwent for 12 weeks."1.43Physiological and microbiological verification of the benefit of hair washing in patients with skin conditions of the scalp. ( Ito, K; Kobayashi, M; Matsunaka, H; Murakami, Y; Nakamura, M; Sugita, T; Yamashita, R, 2016)
"A diagnosis of type IV delayed hypersensitivity reaction was made."1.40Severe facial swelling in a pregnant woman after using hair dye. ( Carels, G; Dees, A; Lonnee, ER; van Genderen, ME, 2014)
"The diagnosis of an eosinophilic arteritis of the scalp may only be considered if the examination of the other peripheral vessels is normal and if the course of the disease is benign, without any treatment, in spite of a persistent blood eosinophilia."1.31[Eosinophilic arteritis of the scalp]. ( Asch, PH; Grosshans, E, 2001)

Research

Studies (66)

TimeframeStudies, this research(%)All Research%
pre-19909 (13.64)18.7374
1990's2 (3.03)18.2507
2000's8 (12.12)29.6817
2010's33 (50.00)24.3611
2020's14 (21.21)2.80

Authors

AuthorsStudies
Massiot, P1
Reygagne, P1
Chagnoleau, C1
Kanoun-Copy, L1
Pouradier, F1
Loussouarn, G1
Queille-Roussel, C1
Jouni, H1
Kerob, D1
Patel, T1
Yosipovitch, G5
Levesque, A1
Hamzavi, I1
Seite, S1
Rougier, A1
Bissonnette, R1
Moy, RL1
Levenson, C1
So, JJ1
Rock, JA1
Thomsen, JS1
Simonsen, L1
Benfeldt, E1
Jensen, SB1
Serup, J1
PERLMAN, HH1
MEYER ZU SCHWEICHELN, H1
Thaçi, D1
Daiber, W1
Boehncke, WH1
Kaufmann, R1
Rupert, J1
Honeycutt, JD1
Ju, T1
Vander Does, A1
Martin, E1
Zhang, A1
Campiche, R1
Kang, SY1
Choi, MG1
Wei, ET1
Selescu, T1
Lee, SY1
Kim, JC1
Chung, BY1
Park, CW1
Kim, HO1
Kaliyadan, F1
Jayasree, P1
Ashique, KT1
Li, X1
Yang, F1
Yan, H1
Shi, Y1
Chang, X1
Zhang, M2
Zhang, Y1
Staubach, P1
Wurzer, E1
Hutt, HJ1
von Kiedrowski, R1
Yao, B1
Yue, X1
Liu, G1
de Jesus, GFA1
Rossetto, MP1
Voytena, A1
Feder, B1
Borges, H1
da Costa Borges, G1
Feuser, ZP1
Dal-Bó, S1
Michels, M1
Nattkemper, LA1
Lipman, ZM1
Ingrasci, G1
Maldonado, C1
Garces, JC1
Loayza, E1
Starace, M1
Pampaloni, F1
Bruni, F1
Quadrelli, F1
Cedirian, S1
Baraldi, C1
Misciali, C1
Di Martino, A1
Sabatelli, P1
Merlini, L1
Piraccini, BM1
Andersen, PL1
Jemec, GB1
Arendrup, MC1
Saunte, DM1
Bucko, AD1
Jarratt, M1
Stough, DB1
Kyhl, L1
Villumsen, J2
Hall, A1
Hanke, CW2
Berman, B1
Swanson, N1
Pariser, DM1
Weiss, JS1
Bukhalo, M1
Skov, T1
Siegel, D1
Feldman, SR1
Green, L1
Kimball, AB1
Siu, K1
Zhao, Y1
Herrera, V1
Nyirady, J1
Alexis, AF1
Xie, Y1
Zhang, Q1
Wang, L1
Laidler, NK1
Chan, J1
Nakamura, Y1
Saito, A1
Takamuki, R1
Inoue, S1
Fujisawa, Y1
Okiyama, N1
Watanabe, R1
Ishitsuka, Y1
Maruyama, H1
Ishii, Y1
Fujimoto, M1
Abdel-Rahman, Z1
Inamdar, K1
Ali, H1
Wang, Y1
Coyne, K1
Sofen, H1
Santanello, N1
Currie, B1
Zhang, Z1
Nograles, K1
Rattanakaemakorn, P1
Suchonwanit, P1
Charlton, D1
Moghadam-Kia, S1
Smith, K1
Aggarwal, R1
English, JC1
Oddis, CV1
Park, KH1
Kim, J1
Oh, B1
Lee, E1
Hwang-Bo, J1
Ha, J1
Schweiger, D1
Baufeld, C1
Drescher, P1
Oltrogge, B1
Höpfner, S1
Mess, A1
Lüttke, J1
Rippke, F1
Filbry, A1
Max, H1
Sarifakioglu, E1
Onur, O1
Yamakoshi, T1
Andoh, T1
Makino, T1
Kuraishi, Y1
Shimizu, T1
van Genderen, ME1
Carels, G1
Lonnee, ER1
Dees, A1
Dolohanty, LB1
Richardson, SJ1
Herrmann, DN1
Markman, J1
Mercurio, MG1
Kronborg, C1
Mahar, P1
Howard, A1
McCrary, WJ1
Hurst, MD1
Hiatt, KM1
Singh, ZN1
Wirges, ML1
Gonul, M1
Benar, H1
Gokce, A1
Shumway, NK1
Cole, E1
Fernandez, KH1
Lynch, MC1
Milchak, MA1
Parnes, H1
Ioffreda, MD1
Kobayashi, M1
Ito, K1
Sugita, T1
Murakami, Y1
Yamashita, R1
Matsunaka, H1
Nakamura, M1
Jun, M1
Lee, NR1
Lee, WS1
Chitgopeker, P1
Lehrer, M1
Landherr, MJ1
Liu, V1
Bernhard, JD1
Samrao, A1
Chew, AL1
Price, V1
Kerr, K1
Schwartz, JR1
Filloon, T1
Fieno, A1
Wehmeyer, K1
Szepietowski, JC1
Mills, KJ1
Bin Saif, GA2
Ericson, ME1
Alajroush, A1
McMichael, A1
Kwatra, SG1
Chan, YH1
McGlone, F2
Takcı, Z1
Tekin, O1
Karadağ, AS1
Meinking, TL1
Mertz-Rivera, K1
Villar, ME1
Bell, M1
Harding, CR1
Moore, AE1
Rogers, JS1
Meldrum, H1
Scott, AE1
McGlone, FP1
Rukwied, R1
Zeck, S1
Schmelz, M1
Piérard-Franchimont, C1
Piérard, GE1
Guarneri, F1
Guarneri, C1
Mento, G1
Ioli, A1
Fallah, H1
Dunlop, K1
Kossard, S1
Jorizzo, JL1
Brenner, S1
Ophir, J1
Krakowski, A1
Bergfeld, WF1
Rauscher, GE1
DiGregorio, VR1
van de Kerkhof, PC1
de Hoop, D1
de Korte, J1
Kuipers, MV1
Moon, CM1
Schissel, DJ1
Grosshans, E1
Asch, PH1
Scribner, M1
Vinas, JC1
Caviglia, C1
Cortinas, JL1
Harris, JJ1

Clinical Trials (4)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase 2B, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate-to-Severe Plaque-Type Psoriasis (Core Study)[NCT00773734]Phase 2352 participants (Actual)Interventional2008-09-01Completed
A Phase 3, Multi-Center, Randomized, Placebo-Controlled, Double-Blind, Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis of the Scalp[NCT03123471]Phase 3303 participants (Actual)Interventional2017-05-16Completed
Treatment Results for Patients With Central Centrifugal Cicatricial Alopecia (CCCA): a Multicenter Prospective Study[NCT04207931]Phase 4250 participants (Anticipated)Interventional2018-04-30Recruiting
A Double-Blind, Placebo-Controlled Study Comparing the Safety and Efficacy of 3 Strengths of Ivermectin Treatment Conditioner and Placebo in Subjects With Pediculus Humanus Capitis (Head Lice) Infestation[NCT00857948]Phase 278 participants (Actual)Interventional2009-03-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Core Study: Area Under the Plasma Concentration-time Curve (AUC0-8)

Area under the concentration versus time curve from time 0 (pre-dose) to 8 hours, calculate using the linear trapezoid rule. (NCT00773734)
Timeframe: Week 24

Interventionng*h/mL (Geometric Mean)
Apremilast 10mg1200
Apremilast 20mg1257
Apremilast 30 mg3477

Core Study: Area Under the Plasma Concentration-time Curve (AUC0-8)

Area under the concentration versus time curve from time 0 (pre-dose) to 8 hours, calculated using the linear trapezoid rule. (NCT00773734)
Timeframe: Week 14; Predose, 0.5, 1, 2, 3, 4, and 8 hours after the morning dose of apremilast

Interventionng*h/mL (Geometric Mean)
Apremilast 10mg BID1008
Apremilast 20mg BID1591
Apremilast 30 mg BID3467

Core Study: Change From Baseline in Dermatology Life Quality Index (DLQI) at Week 16

The DLQI was a validated, self-administered, 10-item questionnaire that measures the impact of skin disease on subjects' quality of life, based on recall over the past week. Domains include symptoms, feelings, daily activities, social, leisure, work or studying, personal relationships and treatment. Each question on the extent of the impact of skin disease was answered on a scale of 0 (not at all) to 3 (very much); the total DLQI score ranged from 0 to 30. A DLQI score greater than 10 is indicative of severe psoriasis. (NCT00773734)
Timeframe: Week 0 to Week 16

Interventionunits on a scale (Least Squares Mean)
Placebo BID-1.9
Apremilast 10mg BID-3.2
Apremilast 20mg BID-5.9
Apremilast 30 mg BID-4.4

Core Study: Change From Baseline in Dermatology Life Quality Index (DLQI) at Week 24

The DLQI was a validated, self-administered, 10-item questionnaire that measures the impact of skin disease on subjects' quality of life, based on recall over the past week. Domains include symptoms, feelings, daily activities, social, leisure, work or studying, personal relationships and treatment. Each question on the extent of the impact of skin disease was answered on a scale of 0 (not at all) to 3 (very much); the total DLQI score ranged from 0 to 30. A DLQI score greater than 10 is indicative of severe psoriasis. (NCT00773734)
Timeframe: Week 0 to Week 24

Interventionunits on a scale (Mean)
Apremilast 10mg BID-3.4
Apremilast 20mg BID-6.2
Apremilast 30 mg BID-4.9
Placebo-Apremilast (APR) 20 mg BID-6.4
Placebo-Apremilast 30 mg BID-5.4

Core Study: Change From Baseline in the Medical Outcome Study Short Form 36-Item Health Survey (SF-36), Version 2 Physical Component Summary Score at Week 24

The SF-36 was a 36-item general health status instrument and consists of 8 scales: physical function (PF), role limitations-physical (RP), vitality (VT), general health perceptions (GH), bodily pain (BP), social function (SF), role limitations-emotional (RE), and mental health (MH). Scale scores range from 0 to 100, with higher scores indicating better health. Two overall summary scores were obtained - a Physical Component Summary score (PCS) and a Mental Component Summary score (MCS). Scores from the 8 scales, PCS and MCS were transformed to the norm-based scores using weights from U.S. general population, with 50 as the average and 10 as the standard deviation, higher scores indicating better health. For norm based scores, change from baseline were calculated for the 8 scales and the two summary scales, where change = visit value - baseline value. (NCT00773734)
Timeframe: Week 0 to Week 24

Interventionunits on a scale (Mean)
Apremilast 10mg BID1.1
Apremilast 20mg BID2.3
Apremilast 30 mg BID1.0
PBO-Apremilast 20mg BID2.5
PBO-Apremilast 30 mg BID2.7

Core Study: Change From Baseline in the Medical Outcome Study Short Form 36-Item Health Survey (SF-36), Version 2; Mental Component Summary Score at Week 16

The SF-36 was a 36-item general health status instrument and consists of 8 scales: physical function (PF), role limitations-physical (RP), vitality (VT), general health perceptions (GH), bodily pain (BP), social function (SF), role limitations-emotional (RE), and mental health (MH). Scale scores range from 0 to 100, with higher scores indicating better health. Two overall summary scores were obtained - a Physical Component Summary score (PCS) and a Mental Component Summary score (MCS). Scores from the 8 scales, PCS and MCS were transformed to the norm-based scores using weights from U.S. general population, with 50 as the average and 10 as the standard deviation, higher scores indicating better health. For norm based scores, change from baseline were calculated for the 8 scales and the two summary scales, where change = visit value - baseline value. (NCT00773734)
Timeframe: Week 0 to Week 16

Interventionunits on a scale (Least Squares Mean)
Placebo BID-0.6
Apremilast 10mg BID2.8
Apremilast 20mg BID2.9
Apremilast 30 mg BID3.0

Core Study: Change From Baseline in the Medical Outcome Study Short Form 36-Item Health Survey (SF-36), Version 2; Mental Component Summary Score at Week 24

The SF-36 was a 36-item general health status instrument and consists of 8 scales: physical function (PF), role limitations-physical (RP), vitality (VT), general health perceptions (GH), bodily pain (BP), social function (SF), role limitations-emotional (RE), and mental health (MH). Scale scores range from 0 to 100, with higher scores indicating better health. Two overall summary scores were obtained - a Physical Component Summary score (PCS) and a Mental Component Summary score (MCS). Scores from the 8 scales, PCS and MCS were transformed to the norm-based scores using weights from U.S. general population, with 50 as the average and 10 as the standard deviation, higher scores indicating better health. For norm based scores, change from baseline were calculated for the 8 scales and the two summary scales, where change = visit value - baseline value. (NCT00773734)
Timeframe: Week 0 to Week 24

Interventionunits on a scale (Mean)
Apremilast 10mg BID2.8
Apremilast 20mg BID3.9
Apremilast 30 mg BID2.9
PBO-Apremilast 20mg BID2.8
PBO-Apremilast 30 mg BID0.5

Core Study: Change From Baseline in the Medical Outcome Study Short Form 36-Item Health Survey (SF-36), Version 2; Physical Component Summary Score at Week 16

The SF-36 was a 36-item general health status instrument and consists of 8 scales: physical function (PF), role limitations-physical (RP), vitality (VT), general health perceptions (GH), bodily pain (BP), social function (SF), role limitations-emotional (RE), and mental health (MH). Scale scores range from 0 to 100, with higher scores indicating better health. Two overall summary scores were obtained - a Physical Component Summary score (PCS) and a Mental Component Summary score (MCS). Scores from the 8 scales, PCS and MCS were transformed to the norm-based scores using weights from U.S. general population, with 50 as the average and 10 as the standard deviation, higher scores indicating better health. For norm based scores, change from baseline were calculated for the 8 scales and the two summary scales, where change = visit value - baseline value. (NCT00773734)
Timeframe: Week 0 to week 16

Interventionunits on a scale (Least Squares Mean)
Placebo BID0.7
Apremilast 10mg BID1.3
Apremilast 20mg BID2.1
Apremilast 30 mg BID0.8

Core Study: Peak; (Maximum) Plasma Concentration (Cmax) of Apremilast

The maximum observed plasma concentration of apremilast observed at Week 14 (steady-state Cmax) (NCT00773734)
Timeframe: Week 14; Predose, 0.5, 1, 2, 3, 4, and 8 hours after the morning dose of apremilast

Interventionng/mL (Geometric Mean)
Apremilast 10mg BID209
Apremilast 20mg BID298
Apremilast 30 mg BID637

Core Study: Peak; (Maximum) Plasma Concentration (Cmax) of Apremilast

The maximum observed plasma concentration of apremilast observed at Week 24 (steady-state Cmax) (NCT00773734)
Timeframe: Week 24

Interventionng/mL (Geometric Mean)
Apremilast 10mg BID238
Apremilast 20mg BID236
Apremilast 30 mg BID670

Core Study: Percent Change From Baseline in PASI Score at Week 16

The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling were scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions was scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The total qualitative score (sum of erythema, thickness, and scaling scores) was multiplied by the degree of involvement for each anatomic region and then multiplied by a constant. The values for each anatomic region were summed to yield the PASI score. (NCT00773734)
Timeframe: Week 0 to Week 16

InterventionPercent change (Least Squares Mean)
Placebo BID-20.3
Apremilast 10mg BID-34.0
Apremilast 20mg BID-45.4
Apremilast 30 mg BID-53.2

Core Study: Percent Change From Baseline in PASI Score at Week 24

The PASI is a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling were scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions was scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The total qualitative score (sum of erythema, thickness, and scaling scores) was multiplied by the degree of involvement for each anatomic region and then multiplied by a constant. The values for each anatomic region were summed to yield the PASI score (NCT00773734)
Timeframe: Week 0 to Week 24

Interventionpercent change (Mean)
Apremilast 10mg BID-36.3
Apremilast 20mg BID-46.5
Apremilast 30 mg BID-56.8
PBO-Apremilast 20mg BID-61.7
PBO-Apremilast 30 mg BID-61.7

Core Study: Percent Change From Baseline in the Percent of Affected Body Surface Area (BSA) During the Active Treatment Phase at Week 24

"The overall BSA affected by psoriasis was estimated by comparison of the size of the affected area to the palm area of the participant's hand (entire palmar surface or handprint), which equates to approximately 1% of total BSA." (NCT00773734)
Timeframe: Week 0 to Week 24

Interventionpercent change (Mean)
Apremilast 10mg BID-28.1
Apremilast 20mg BID-40.6
Apremilast 30 mg BID-54.0
Placebo-Apremilast 20 mg BID-52.5
Placebo-Apremilast 30 mg BID-54.2

Core Study: Percent Change From Baseline in the Percent of Affected Body Surface Area (BSA) During the Placebo Controlled Phase

"The overall BSA affected by psoriasis was estimated by comparison of the size of the affected area to the palm area of the participant's hand (entire palmar surface or handprint), which equates to approximately 1% of total BSA." (NCT00773734)
Timeframe: Week 0 to Week 16

Interventionpercent change (Least Squares Mean)
Placebo BID-8.0
Apremilast 10mg BID-28.3
Apremilast 20mg BID-38.0
Apremilast 30 mg BID-50.4

Core Study: Percentage of Participants Who Achieved a 50% Improvement (Response) in PASI Score at Week 16

PASI-50 response is the percentage of participants who achieved at least a 50% reduction (improvement) from baseline in PASI score at Week 16. The improvement in PASI score was used as a measure of efficacy The PASI score was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). (NCT00773734)
Timeframe: Week 0 to Week 16

Interventionpercentage of participants (Number)
Placebo BID25.0
Apremilast 10mg BID38.2
Apremilast 20mg BID47.1
Apremilast 30 mg BID60.2

Core Study: Percentage of Participants Who Achieved a 50% Improvement (Response) in the PASI Score at Week 24

PASI-50 response is the percentage of participants who achieved at least a 50% reduction (improvement) from baseline in PASI score at Week 24. The improvement in PASI score was used as a measure of efficacy. The PASI score was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). (NCT00773734)
Timeframe: Week 0 to Week 24

Interventionpercentage of participants (Number)
Apremilast 10mg BID38.2
Apremilast 20mg49.4
Apremilast 30 mg BID65.9
Placebo-Apremilast 20mg BID61.8
PBO-Apremilast 30 mg BID75.0

Core Study: Percentage of Participants Who Achieved a 75% Improvement (Response) in PASI Score at Week 24

PASI-75 response is the percentage of participants who achieved at least a 75% reduction (improvement) from baseline in PASI score at Week 24. The improvement in PASI score was used as a measure of efficacy.The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head,trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). (NCT00773734)
Timeframe: Week 0 to Week 24

Interventionpercentage of participants (Number)
Apremilast 10mg BID18.0
Apremilast 20mg BID26.4
Apremilast 30 mg BID39.8
PBO-Apremilast 20mg BID41.2
PBO-Apremilast 30 mg BID44.4

Core Study: Percentage of Participants Who Achieved a 75% Improvement (Response) in Psoriasis Area and Severity Index (PASI) at Week 16

PASI-75 response is the percentage of participants who achieved at least a 75% reduction (improvement) from baseline in PASI score at Week 16. The improvement in PASI score was used as a measure of efficacy. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). (NCT00773734)
Timeframe: Week 0 and Week 16

Interventionpercentage of participants (Number)
Placebo BID5.7
Apremilast 10mg BID11.2
Apremilast 20mg BID28.7
Apremilast 30 mg BID40.9

Core Study: Percentage of Participants Who Achieved a 90% Improvement (Response) From Baseline in the PASI Score at Week 16

PASI-90 response is the percentage of participants who achieved at least a 90% reduction (improvement) from baseline in PASI score at Week 16. The improvement in PASI score was used as a measure of efficacy. The PASI score was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). (NCT00773734)
Timeframe: Week 0 to Week 16

Interventionpercentage of participants (Number)
Placebo BID1.1
Apremilast 10mg BID4.5
Apremilast 20mg BID9.2
Apremilast 30 mg BID11.4

Core Study: Percentage of Participants Who Achieved a 90% Improvement (Response) in the PASI Score at Week 24

PASI-90 response is the percentage of participants who achieved at least a 90% reduction (improvement) from baseline in PASI score at Week 24. The improvement in PASI score was used as a measure of efficacy..The PASI is a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling were scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions was scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). (NCT00773734)
Timeframe: Week 0 to Week 24

Interventionpercentage of participants (Number)
Apremilast 10mg4.5
Apremilast 20mg8.0
Apremilast 30 mg14.8
PBO-Apremilast 20mg BID14.7
Placebo-Apremilast 30 mg BID16.7

Core Study: Percentage of Participants Who Achieved a Static Physician Global Assessment (sPGA) Score of 0 or 1 at Week 24

The sPGA was a measure of psoriasis disease severity at the time of evaluation by the investigator. It does not compare assessments across visits or rely on investigator recall of prior disease severity. The sPGA was a 6-point scale ranging from 0 (clear, except for residual discoloration) to 5 (severe; majority of plaques have severe thickness, erythema, and scaling). The investigator examined all of the lesions on the participant and assigned a score ranging from 0 to 5 for thickness, erythema and degree of scaling . Scores for thickness, erythema and scaling are then summed and the mean of these 3 scores equaled the overall sPGA score. Fractional values for the sPGA were rounded to the next highest integer (eg, a score of 3.5 was rounded to 4, 3.4 was rounded to 3). A lower sPGA score was associated with less severe disease (NCT00773734)
Timeframe: Week 0 and Week 24

Interventionpercentage of participants (Number)
Apremilast 10mg BID13.5
Apremilast 20mg BID24.1
Apremilast 30 mg BID34.1
Placebo-Apremilast 20 mg BID41.2
Placebo-Apremilast 30 mg BID50.0

Core Study: Percentage of Participants With a Static Physician Global Assessment (sPGA) Greater Than 2 at Baseline Who Achieved a Score of 0 or 1 at Week 16

The sPGA was a measure of psoriasis disease severity at the time of evaluation by the investigator. It does not compare assessments across visits or rely on investigator recall of prior disease severity. The sPGA was a 6-point scale ranging from 0 (clear, except for residual discoloration) to 5 (severe; majority of plaques have severe thickness, erythema, and scaling). The investigator examined all of the lesions on the participant and assigned a score ranging from 0 to 5 for thickness, erythema and degree of scaling . Scores for thickness, erythema and scaling are then summed and the mean of these 3 scores equaled the overall sPGA score. Fractional values for the sPGA were rounded to the next highest integer (eg, a score of 3.5 was rounded to 4, 3.4 was rounded to 3). A lower sPGA score was associated with less severe disease (NCT00773734)
Timeframe: Week 0 to Week 16

Interventionpercentage of participants (Number)
Placebo12.6
Apremilast 10mg10.5
Apremilast 20mg25.0
Apremilast 30 mg33.7

Core Study: Time to Achieve a PASI-50 Response During the Placebo Controlled Phase

For PASI-50 responders in the placebo-controlled period weeks 0-16, time to achieve PASI-50 was defined as the time interval, inclusive between the date of randomization (day 1) and the date of the first assessment where PASI-50 was achieved. (NCT00773734)
Timeframe: Week 0 to 16

Interventionweeks (Median)
Placebo BID6.5
Apremilast 10mg BID5.9
Apremilast 20mg BID6.0
Apremilast 30 mg BID4.3

Core Study: Time to Achieve a PASI-75 Response During the Placebo Controlled Phase

For PASI-75 responders in the placebo-controlled period Weeks 0-16, time to achieve PASI-75 was defined as the time interval, inclusive between the date of randomization (day 1) and the date of the first assessment where PASI-75 is achieved. (NCT00773734)
Timeframe: Weeks 0 to 16

Interventionweeks (Median)
Placebo BID8.1
Apremilast 10mg BID10.0
Apremilast 20mg BID11.9
Apremilast 30 mg BID6.3

Core Study: Time to Maximum Plasma Concentration of Drug (Tmax)

Time to achieve maximum plasma concentration (Cmax) observed at Week 14 (Time to achieve steady-state Tmax) (NCT00773734)
Timeframe: Week 14; Predose, 0.5, 1, 2, 3, 4, and 8 hours after the morning dose of apremilast

Interventionhours (Median)
Apremilast 10mg BID2.00
Apremilast 20mg BID2.00
Apremilast 30 mg BID1.00

Core Study: Time to Maximum Plasma Concentration of Drug (Tmax)

Time to achieve maximum plasma concentration (tmax) observed at Week 24 (Time to achieve steady-state Tmax) (NCT00773734)
Timeframe: Week 24

Interventionhours (Median)
Apremilast 10mg BID1.00
Apremilast 20mg BID1.50
Apremilast 30 mg BID1.00

Extension Study: Change From Baseline in Dermatology Life Quality Index (DLQI) at Week 32

The DLQI was a validated, self-administered, 10-item questionnaire that measures the impact of skin disease on subjects' quality of life, based on recall over the past week. Domains include symptoms, feelings, daily activities, social, leisure, work or studying, personal relationships and treatment. Each question on the extent of the impact of skin disease was answered on a scale of 0 (not at all) to 3 (very much); the total DLQI score ranged from 0 to 30. A DLQI score greater than 10 is indicative of severe psoriasis. (NCT00773734)
Timeframe: Week 0 to Week 32

Interventionunits on a scale (Mean)
Apremilast 10mg BID-6.5
Apremilast 20mg BID-7.5
Apremilast 30 mg BID-6.0
Placebo-Apremilast 20mg BID-8.1
Placebo-Apremilast 30 mg BID5.5

Extension Study: Change From Baseline in Dermatology Life Quality Index (DLQI) at Week 40

The DLQI was a validated, self-administered, 10-item questionnaire that measures the impact of skin disease on subjects' quality of life, based on recall over the past week. Domains include symptoms, feelings, daily activities, social, leisure, work or studying, personal relationships and treatment. Each question on the extent of the impact of skin disease was answered on a scale of 0 (not at all) to 3 (very much); the total DLQI score ranged from 0 to 30. A DLQI score greater than 10 is indicative of severe psoriasis. (NCT00773734)
Timeframe: Week 0 to Week 40

Interventionunits on a scale (Mean)
Apremilast 10mg BID-5.5
Apremilast 20mg BID-6.6
Apremilast 30 mg BID-6.4
Placebo-Apremilast 20mg BID-7.1
Placebo-Apremilast 30 mg BID-5.9

Extension Study: Change From Baseline in Dermatology Life Quality Index (DLQI) at Week 52

The DLQI was a validated, self-administered, 10-item questionnaire that measures the impact of skin disease on subjects' quality of life, based on recall over the past week. Domains include symptoms, feelings, daily activities, social, leisure, work or studying, personal relationships and treatment. Each question on the extent of the impact of skin disease was answered on a scale of 0 (not at all) to 3 (very much); the total DLQI score ranged from 0 to 30. A DLQI score greater than 10 is indicative of severe psoriasis. (NCT00773734)
Timeframe: Week 0 to Week 52

Interventionunits on a scale (Mean)
Apremilast 10mg BID-5.8
Apremilast 20mg BID-6.1
Apremilast 30 mg BID-5.6
Placebo-Apremilast 20mg BID-6.8
Placebo-Apremilast 30 mg BID-4.9

Extension Study: Change From Baseline in Medical Outcome Study Short Form,SF-36, Version 2; Physical Component Summary Score at Week 40

The SF-36 was a 36-item general health status instrument and consists of 8 scales: physical function (PF), role limitations-physical (RP), vitality (VT), general health perceptions (GH), bodily pain (BP), social function (SF), role limitations-emotional (RE), and mental health (MH). Scale scores range from 0 to 100, with higher scores indicating better health. Two overall summary scores were obtained - a Physical Component Summary score (PCS) and a Mental Component Summary score (MCS). Scores from the 8 scales, PCS and MCS were transformed to the norm-based scores using weights from U.S. general population, with 50 as the average and 10 as the standard deviation, higher scores indicating better health. For norm based scores, change from baseline were calculated for the 8 scales and the two summary scales, where change = visit value - baseline value. (NCT00773734)
Timeframe: Week 0 to Week 40

Interventionunits on a scale (Mean)
Apremilast 10mg BID-0.2
Apremilast 20mg BID1.6
Apremilast 30 mg BID1.7
Placebo-Apremilast 20mg BID3.2
Placebo-Apremilast 30 mg BID1.8

Extension Study: Change From Baseline in the Medical Outcome Study Short Form,SF-36, Version 2; Mental Component Summary Score at Week 32

The SF-36 was a 36-item general health status instrument and consists of 8 scales: physical function (PF), role limitations-physical (RP), vitality (VT), general health perceptions (GH), bodily pain (BP), social function (SF), role limitations-emotional (RE), and mental health (MH). Scale scores range from 0 to 100, with higher scores indicating better health. Two overall summary scores were obtained - a Physical Component Summary score (PCS) and a Mental Component Summary score (MCS). Scores from the 8 scales, PCS and MCS were transformed to the norm-based scores using weights from U.S. general population, with 50 as the average and 10 as the standard deviation, higher scores indicating better health. For norm based scores, change from baseline were calculated for the 8 scales and the two summary scales, where change = visit value - baseline value. (NCT00773734)
Timeframe: Week 0 to Week 32

Interventionunits on a scale (Mean)
Apremilast 10mg BID5.2
Apremilast 20mg BID3.8
Apremilast 30 mg BID2.9
Placebo-Apremilast 20mg BID4.6
Placebo-Apremilast 30 mg BID2.8

Extension Study: Change From Baseline in the Medical Outcome Study Short Form,SF-36, Version 2; Mental Component Summary Score at Week 40

The SF-36 was a 36-item general health status instrument and consists of 8 scales: physical function (PF), role limitations-physical (RP), vitality (VT), general health perceptions (GH), bodily pain (BP), social function (SF), role limitations-emotional (RE), and mental health (MH). Scale scores range from 0 to 100, with higher scores indicating better health. Two overall summary scores were obtained - a Physical Component Summary score (PCS) and a Mental Component Summary score (MCS). Scores from the 8 scales, PCS and MCS were transformed to the norm-based scores using weights from U.S. general population, with 50 as the average and 10 as the standard deviation, higher scores indicating better health. For norm based scores, change from baseline were calculated for the 8 scales and the two summary scales, where change = visit value - baseline value. (NCT00773734)
Timeframe: Week 0 to Week 40

Interventionunits on a scale (Mean)
Apremilast 10mg BID5.4
Apremilast 20mg BID4.8
Apremilast 30 mg BID1.7
Placebo-Apremilast 20mg BID2.9
Placebo-Apremilast 30 mg BID3.8

Extension Study: Change From Baseline in the Medical Outcome Study Short Form,SF-36, Version 2; Mental Component Summary Score at Week 52

The SF-36 was a 36-item general health status instrument and consists of 8 scales: physical function (PF), role limitations-physical (RP), vitality (VT), general health perceptions (GH), bodily pain (BP), social function (SF), role limitations-emotional (RE), and mental health (MH). Scale scores range from 0 to 100, with higher scores indicating better health. Two overall summary scores were obtained - a Physical Component Summary score (PCS) and a Mental Component Summary score (MCS). Scores from the 8 scales, PCS and MCS were transformed to the norm-based scores using weights from U.S. general population, with 50 as the average and 10 as the standard deviation, higher scores indicating better health. For norm based scores, change from baseline were calculated for the 8 scales and the two summary scales, where change = visit value - baseline value. (NCT00773734)
Timeframe: Week 0 to Week 52

Interventionunits on a scale (Mean)
Apremilast 10mg BID5.1
Apremilast 20mg BID4.1
Apremilast 30 mg BID2.4
Placebo-Apremilast 20mg BID4.7
Placebo-Apremilast 30 mg BID3.4

Extension Study: Change From Baseline in the Medical Outcome Study Short Form,SF-36, Version 2; Physical Component Summary Score (PCS) at Week 32

The SF-36 was a 36-item general health status instrument and consists of 8 scales: physical function (PF), role limitations-physical (RP), vitality (VT), general health perceptions (GH), bodily pain (BP), social function (SF), role limitations-emotional (RE), and mental health (MH). Scale scores range from 0 to 100, with higher scores indicating better health. Two overall summary scores were obtained - a Physical Component Summary score (PCS) and a Mental Component Summary score (MCS). Scores from the 8 scales, PCS and MCS were transformed to the norm-based scores using weights from U.S. general population, with 50 as the average and 10 as the standard deviation, higher scores indicating better health. For norm based scores, change from baseline were calculated for the 8 scales and the two summary scales, where change = visit value - baseline value. (NCT00773734)
Timeframe: Week 0 to Week 32

Interventionunits on a scale (Mean)
Apremilast 10mg BID1.4
Apremilast 20mg BID2.6
Apremilast 30 mg BID1.8
Placebo-Apremilast 20mg BID3.1
Placebo-Apremilast 30 mg BID1.5

Extension Study: Change From Baseline in the Medical Outcome Study Short Form,SF-36, Version 2; Physical Component Summary Score at Week 52

The SF-36 was a 36-item general health status instrument and consists of 8 scales: physical function (PF), role limitations-physical (RP), vitality (VT), general health perceptions (GH), bodily pain (BP), social function (SF), role limitations-emotional (RE), and mental health (MH). Scale scores range from 0 to 100, with higher scores indicating better health. Two overall summary scores were obtained - a Physical Component Summary score (PCS) and a Mental Component Summary score (MCS). Scores from the 8 scales, PCS and MCS were transformed to the norm-based scores using weights from U.S. general population, with 50 as the average and 10 as the standard deviation, higher scores indicating better health. For norm based scores, change from baseline were calculated for the 8 scales and the two summary scales, where change = visit value - baseline value.. (NCT00773734)
Timeframe: Week 0 to Week 52

Interventionunits on a scale (Mean)
Apremilast 10mg BID1.2
Apremilast 20mg BID1.2
Apremilast 30 mg BID2.0
Placebo-Apremilast 20mg BID3.4
Placebo-Apremilast 30 mg BID0.3

Extension Study: Percent Change From Baseline in the Affected BSA at Week 32

"The overall BSA affected by psoriasis was estimated by comparison of the size of the affected area to the palm area of the participant's hand (entire palmar surface or handprint), which equates to approximately 1% of total BSA." (NCT00773734)
Timeframe: Week 0 to Week 32

Interventionpercent change (Mean)
Apremilast 10mg BID-47.1
Apremilast 20mg BID-65.1
Apremilast 30 mg BID-75.3
Placebo-Apremilast 20mg BID-62.6
Placebo-Apremilast 30 mg BID-66.7

Extension Study: Percent Change From Baseline in the Affected BSA at Week 40

"The overall BSA affected by psoriasis was estimated by comparison of the size of the affected area to the palm area of the participant's hand (entire palmar surface or handprint), which equates to approximately 1% of total BSA." (NCT00773734)
Timeframe: Week 0 to Week 40

Interventionpercent change (Mean)
Apremilast 10mg BID-55.4
Apremilast 20mg BID-65.4
Apremilast 30 mg BID-74.3
Placebo-Apremilast 20mg BID-66.2
Placebo-Apremilast 30 mg BID-68.0

Extension Study: Percent Change From Baseline in the Affected BSA at Week 52

"The overall BSA affected by psoriasis was estimated by comparison of the size of the affected area to the palm area of the participant's hand (entire palmar surface or handprint), which equates to approximately 1% of total BSA." (NCT00773734)
Timeframe: Week 0 to Week 52

Interventionpercent change (Mean)
Apremilast 10mg BID-53.1
Apremilast 20mg BID-58.3
Apremilast 30 mg BID-67.3
Placebo-Apremilast 20mg BID-67.4
Placebo-Apremilast 30 mg BID-64.9

Extension Study: Percent Change in PASI Score at Week 32

The PASI is a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling were scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions was scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The total qualitative score (sum of erythema, thickness, and scaling scores) was multiplied by the degree of involvement for each anatomic region and then multiplied by a constant. The values for each anatomic region were summed to yield the PASI score (NCT00773734)
Timeframe: Week 0 to Week 32

Interventionpercent change (Mean)
Apremilast 10mg BID-51.0
Apremilast 20mg BID-63.1
Apremilast 30 mg BID-72.7
Placebo-Apremilast 20mg BID-64.0
Placebo-Apremilast 30 mg BID-69.2

Extension Study: Percent Change in PASI Score at Week 40

The PASI is a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling were scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions was scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The total qualitative score (sum of erythema, thickness, and scaling scores) was multiplied by the degree of involvement for each anatomic region and then multiplied by a constant. The values for each anatomic region were summed to yield the PASI score (NCT00773734)
Timeframe: Week 0 to Week 40

Interventionpercent change (Mean)
Apremilast 10mg BID-55.9
Apremilast 20mg BID-63.3
Apremilast 30 mg BID-71.1
Placebo-Apremilast 20mg BID-64.5
Placebo-Apremilast 30 mg BID-71.7

Extension Study: Percent Change in PASI Score at Week 52

The PASI is a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling were scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions was scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The total qualitative score (sum of erythema, thickness, and scaling scores) was multiplied by the degree of involvement for each anatomic region and then multiplied by a constant. The values for each anatomic region were summed to yield the PASI score (NCT00773734)
Timeframe: Week 0 to Week 52

Interventionpercent change (Mean)
Apremilast 10mg BID-55.1
Apremilast 20mg BID-58.9
Apremilast 30 mg BID-65.3
Placebo-Apremilast 20mg BID-62.7
Placebo-Apremilast 30 mg BID-62.0

Extension Study: Percentage of Participants Who Achieved a 50% Improvement (Response) in the PASI Score at Week 32

PASI-50 response is the percentage of participants who achieved at least a 50% reduction (improvement) from baseline in PASI score at Week 32 of the extension study. The improvement in PASI score was used as a measure of efficacy. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). (NCT00773734)
Timeframe: Week 0 to Week 32

Interventionpercentage of participants (Number)
Apremilast 10mg BID57.4
Apremilast 20mg BID72.0
Apremilast 30 mg BID86.2
Placebo-Apremilast 20mg BID74.1
Placebo-Apremilast 30 mg BID74.1

Extension Study: Percentage of Participants Who Achieved a 50% Improvement (Response) in the PASI Score at Week 40

PASI-50 response is the percentage of participants who achieved at least a 50% reduction (improvement) from baseline in PASI score at Week 16 of the extension study. The improvement in PASI score was used as a measure of efficacy. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). (NCT00773734)
Timeframe: Week 0 to Week 40

Interventionpercentage of participants (Number)
Apremilast 10mg BID48.9
Apremilast 20mg BID62.0
Apremilast 30 mg BID82.8
Placebo-Apremilast 20mg BID63.0
Placebo-Apremilast 30 mg BID66.7

Extension Study: Percentage of Participants Who Achieved a 50% Improvement (Response) in the PASI Score at Week 52

PASI-50 response is the percentage of participants who achieved at least a 50% reduction (improvement) from baseline in PASI score at Week 52 of the extension study. The improvement in PASI score was used as a measure of efficacy. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). (NCT00773734)
Timeframe: Week 0 to Week 52

Interventionpercentage of participants (Number)
Apremilast 10mg BID42.6
Apremilast 20mg BID48.0
Apremilast 30 mg BID72.4
Placebo-Apremilast 20mg BID55.6
Placebo-Apremilast 30 mg BID48.1

Extension Study: Percentage of Participants Who Achieved a 75% Improvement (Response) in the PASI Score at Week 32

PASI-75 response is the percentage of participants who achieved at least a 75% reduction (improvement) from baseline in PASI score at Week 32 of the extension study. The improvement in PASI score was used as a measure of efficacy. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). (NCT00773734)
Timeframe: Week 0 to Week 32

Interventionpercentage of participants (Number)
Apremilast 10mg BID27.7
Apremilast 20mg BID38.0
Apremilast 30 mg BID46.6
Placebo-Apremilast 20mg BID33.3
Placebo-Apremilast 30 mg BID55.6

Extension Study: Percentage of Participants Who Achieved a 75% Improvement (Response) in the PASI Score at Week 40

PASI-75 response is the percentage of participants who achieved at least a 75% reduction (improvement) from baseline in PASI score at Week 40 of the extension study. The improvement in PASI score was used as a measure of efficacy. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). (NCT00773734)
Timeframe: Week 0 to Week 40

Interventionpercentage of participants (Number)
Apremilast 10mg BID21.3
Apremilast 20mg BID28.0
Apremilast 30 mg BID34.5
Placebo-Apremilast 20mg BID37.0
Placebo-Apremilast 30 mg BID44.4

Extension Study: Percentage of Participants Who Achieved a 75% Improvement (Response) in the PASI Score at Week 52

PASI-75 response is the percentage of participants who achieved at least a 75% reduction (improvement) from baseline in PASI score at Week 52. The improvement in PASI score was used as a measure of efficacy. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). (NCT00773734)
Timeframe: Week 0 to Week 52

Interventionpercentage of participants (Number)
Apremilast 10mg BID14.9
Apremilast 20mg BID22.0
Apremilast 30 mg BID36.2
Placebo-Apremilast 20mg BID37.0
Placebo-Apremilast 30 mg BID33.3

Extension Study: Percentage of Participants Who Achieved a 90% Improvement (Response) in the PASI Score at Week 32

PASI-90 response is the percentage of participants who achieved at least a 90% reduction (improvement) from baseline in PASI score at Week 32 of the extension study. The improvement in PASI score was used as a measure of efficacy. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). (NCT00773734)
Timeframe: Week 0 to Week 32

Interventionpercentage of participants (Number)
Apremilast 10mg BID10.6
Apremilast 20mg BID14.0
Apremilast 30 mg BID19.0
Placebo-Apremilast 20mg BID18.5
Placebo-Apremilast 30 mg BID25.9

Extension Study: Percentage of Participants Who Achieved a 90% Improvement (Response) in the PASI Score at Week 40

PASI-90 response is the percentage of participants who achieved at least a 90% reduction (improvement) from baseline in PASI score at Week 40 of the extension study. The improvement in PASI score was used as a measure of efficacy. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). (NCT00773734)
Timeframe: Week 0 to Week 40

Interventionpercentage of participants (Number)
Apremilast 10mg BID8.5
Apremilast 20mg BID14.0
Apremilast 30 mg BID17.2
Placebo-Apremilast 20mg BID18.5
Placebo-Apremilast 30 mg BID22.2

Extension Study: Percentage of Participants Who Achieved a 90% Improvement (Response) in the PASI Score at Week 52

PASI-90 response is the percentage of participants who achieved at least a 90% reduction (improvement) from baseline in PASI score at Week 52 of the extension study. The improvement in PASI score was used as a measure of efficacy. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). (NCT00773734)
Timeframe: Week 0 to Week 52

Interventionpercentage of participants (Number)
Apremilast 10mg BID4.3
Apremilast 20mg BID10.0
Apremilast 30 mg BID13.8
Placebo-Apremilast 20mg BID14.8
Placebo-Apremilast 30 mg BID11.1

Extension Study: Percentage of Participants Who Achieved a Static Physician Global Assessment (sPGA) Score of 0 or 1 at Week 32

The sPGA was a measure of psoriasis disease severity at the time of evaluation by the investigator. It does not compare assessments across visits or rely on investigator recall of prior disease severity. The sPGA was a 6-point scale ranging from 0 (clear, except for residual discoloration) to 5 (severe; majority of plaques have severe thickness, erythema, and scaling). The investigator examined all of the lesions on the participant and assigned a score ranging from 0 to 5 for thickness, erythema and degree of scaling . Scores for thickness, erythema and scaling are then summed and the mean of these 3 scores equaled the overall sPGA score. Fractional values for the sPGA were rounded to the next highest integer (eg, a score of 3.5 was rounded to 4, 3.4 was rounded to 3). A lower sPGA score was associated with less severe disease. (NCT00773734)
Timeframe: Week 0 to Week 32

Interventionpercentage of participants (Number)
Apremilast 10mg BID23.4
Apremilast 20mg BID26
Apremilast 30 mg BID44.8
Placebo-Apremilast 20mg BID33.3
Placebo-Apremilast 30 mg BID59.3

Extension Study: Percentage of Participants Who Achieved a Static Physician Global Assessment (sPGA) Score of 0 or 1 at Week 40

The sPGA was a measure of psoriasis disease severity at the time of evaluation by the investigator. It does not compare assessments across visits or rely on investigator recall of prior disease severity. The sPGA was a 6-point scale ranging from 0 (clear, except for residual discoloration) to 5 (severe; majority of plaques have severe thickness, erythema, and scaling). The investigator examined all of the lesions on the participant and assigned a score ranging from 0 to 5 for thickness, erythema and degree of scaling . Scores for thickness, erythema and scaling are then summed and the mean of these 3 scores equaled the overall sPGA score. Fractional values for the sPGA were rounded to the next highest integer (eg, a score of 3.5 was rounded to 4, 3.4 was rounded to 3). A lower sPGA score was associated with less disease. (NCT00773734)
Timeframe: Week 0 to Week 40

Interventionpercentage of participants (Number)
Apremilast 10mg BID23.4
Apremilast 20mg BID18.0
Apremilast 30 mg BID29.3
Placebo-Apremilast 20mg BID29.6
Placebo-Apremilast 30 mg BID37.0

Extension Study: Percentage of Participants Who Achieved a Static Physician Global Assessment (sPGA) Score of 0 or 1 at Week 52

The sPGA was a measure of psoriasis disease severity at the time of evaluation by the investigator. It does not compare assessments across visits or rely on investigator recall of prior disease severity. The sPGA was a 6-point scale ranging from 0 (clear, except for residual discoloration) to 5 (severe; majority of plaques have severe thickness, erythema, and scaling). The investigator examined all of the lesions on the participant and assigned a score ranging from 0 to 5 for thickness, erythema and degree of scaling . Scores for thickness, erythema and scaling are then summed and the mean of these 3 scores equaled the overall sPGA score. Fractional values for the sPGA were rounded to the next highest integer (eg, a score of 3.5 was rounded to 4, 3.4 was rounded to 3). A lower sPGA score was associated with less severe disease. (NCT00773734)
Timeframe: Week 0 to Week 52

Interventionpercentage of participants (Number)
Apremilast 10mg BID12.8
Apremilast 20mg BID10.0
Apremilast 30 mg BID22.4
Placebo-Apremilast 20mg BID33.3
Placebo-Apremilast 30 mg BID22.2

LTE Study: Change From Baseline in the Dermatology Life Quality Index (DLQI) Total Score at 18 Months

The DLQI was a validated, self-administered, 10-item questionnaire that measures the impact of skin disease on subjects' quality of life, based on recall over the past week. Domains include symptoms, feelings, daily activities, social, leisure, work or studying, personal relationships and treatment. Each question on the extent of the impact of skin disease was answered on a scale of 0 (not at all) to 3 (very much); the total DLQI score ranged from 0 to 30. A DLQI score greater than 10 is indicative of severe psoriasis. (NCT00773734)
Timeframe: Week 0 to Month 18

Interventionunits on a scale (Mean)
Apremilast 20mg BID-6.5

LTE Study: Change From Baseline in the Dermatology Life Quality Index (DLQI) Total Score at 2 Years

The DLQI was a validated, self-administered, 10-item questionnaire that measures the impact of skin disease on subjects' quality of life, based on recall over the past week. Domains include symptoms, feelings, daily activities, social, leisure, work or studying, personal relationships and treatment. Each question on the extent of the impact of skin disease was answered on a scale of 0 (not at all) to 3 (very much); the total DLQI score ranged from 0 to 30. A DLQI score greater than 10 is indicative of severe psoriasis. (NCT00773734)
Timeframe: Week 0 to Month 24

Interventionunits on a scale (Mean)
Apremilast 10mg BID-5.2
Placebo-Apremilast 20mg BID-13.5
Apremilast 20mg BID-5.9
Placebo-Apremilast 30 mg BID-1.8
Apremilast 30 mg BID-6.8

LTE Study: Change From Baseline in the Dermatology Life Quality Index (DLQI) Total Score at 3 Years

The DLQI was a validated, self-administered, 10-item questionnaire that measures the impact of skin disease on subjects' quality of life, based on recall over the past week. Domains include symptoms, feelings, daily activities, social, leisure, work or studying, personal relationships and treatment. Each question on the extent of the impact of skin disease was answered on a scale of 0 (not at all) to 3 (very much); the total DLQI score ranged from 0 to 30. A DLQI score greater than 10 is indicative of severe psoriasis. (NCT00773734)
Timeframe: Week 0 to Month 36

Interventionunits on a scale (Mean)
Apremilast 10mg BID-11.7
Placebo-Apremilast 20mg BID-3.0
Apremilast 20mg BID-4.2
Placebo-Apremilast 30 mg BID-2.0
Apremilast 30 mg BID-6.0

LTE Study: Change From Baseline in the Dermatology Life Quality Index (DLQI) Total Score at 4 Years

The DLQI was a validated, self-administered, 10-item questionnaire that measures the impact of skin disease on subjects' quality of life, based on recall over the past week. Domains include symptoms, feelings, daily activities, social, leisure, work or studying, personal relationships and treatment. Each question on the extent of the impact of skin disease was answered on a scale of 0 (not at all) to 3 (very much); the total DLQI score ranged from 0 to 30. A DLQI score greater than 10 is indicative of severe psoriasis. (NCT00773734)
Timeframe: Week 0 to Month 48

Interventionunits on a scale (Mean)
Apremilast 10mg BID-6.0
Placebo-Apremilast 20mg BID-9.0
Apremilast 20mg BID-3.5
Placebo-Apremilast 30 mg BID-7.0
Apremilast 30 mg BID-10.3

LTE Study: Change From Baseline in the Medical Outcome Study Short Form, SF-36, Version 2; Mental Component Summary Score at 18 Months

The SF-36 was a 36-item general health status instrument and consists of 8 scales: physical function (PF), role limitations-physical (RP), vitality (VT), general health perceptions (GH), bodily pain (BP), social function (SF), role limitations-emotional (RE), and mental health (MH). Scale scores range from 0 to 100, with higher scores indicating better health. Two overall summary scores were obtained - a Physical Component Summary score (PCS) and a Mental Component Summary score (MCS). Scores from the 8 scales, PCS and MCS were transformed to the norm-based scores using weights from U.S. general population, with 50 as the average and 10 as the standard deviation, higher scores indicating better health. For norm based scores, change from baseline were calculated for the 8 scales and the two summary scales, where change = visit value - baseline value. (NCT00773734)
Timeframe: Week 0 to Month 18

Interventionunits on a scale (Mean)
Apremilast 20mg BID-2.8

LTE Study: Change From Baseline in the Medical Outcome Study Short Form, SF-36, Version 2; Mental Component Summary Score at 2 Years

The SF-36 was a 36-item general health status instrument and consists of 8 scales: physical function (PF), role limitations-physical (RP), vitality (VT), general health perceptions (GH), bodily pain (BP), social function (SF), role limitations-emotional (RE), and mental health (MH). Scale scores range from 0 to 100, with higher scores indicating better health. Two overall summary scores were obtained - a Physical Component Summary score (PCS) and a Mental Component Summary score (MCS). Scores from the 8 scales, PCS and MCS were transformed to the norm-based scores using weights from U.S. general population, with 50 as the average and 10 as the standard deviation, higher scores indicating better health. For norm based scores, change from baseline were calculated for the 8 scales and the two summary scales, where change = visit value - baseline value. (NCT00773734)
Timeframe: Week 0 to Month 24

Interventionunits on a scale (Mean)
Apremilast 10mg BID5.0
Placebo-Apremilast 20mg BID2.0
Apremilast 20mg BID5.2
Placebo-Apremilast 30 mg BID4.5
Apremilast 30 mg BID0.2

LTE Study: Change From Baseline in the Medical Outcome Study Short Form, SF-36, Version 2; Mental Component Summary Score at 3 Years

The SF-36 was a 36-item general health status instrument and consists of 8 scales: physical function (PF), role limitations-physical (RP), vitality (VT), general health perceptions (GH), bodily pain (BP), social function (SF), role limitations-emotional (RE), and mental health (MH). Scale scores range from 0 to 100, with higher scores indicating better health. Two overall summary scores were obtained - a Physical Component Summary score (PCS) and a Mental Component Summary score (MCS). Scores from the 8 scales, PCS and MCS were transformed to the norm-based scores using weights from U.S. general population, with 50 as the average and 10 as the standard deviation, higher scores indicating better health. For norm based scores, change from baseline were calculated for the 8 scales and the two summary scales, where change = visit value - baseline value. (NCT00773734)
Timeframe: Week 0 to Month 36

Interventionunits on a scale (Mean)
Apremilast 10mg BID6.0
Placebo-Apremilast 20mg BID-2.7
Apremilast 20mg BID3.6
Placebo-Apremilast 30 mg BID2.1
Apremilast 30 mg BID2.4

LTE Study: Change From Baseline in the Medical Outcome Study Short Form, SF-36, Version 2; Mental Component Summary Score at 4 Years

The SF-36 was a 36-item general health status instrument and consists of 8 scales: physical function (PF), role limitations-physical (RP), vitality (VT), general health perceptions (GH), bodily pain (BP), social function (SF), role limitations-emotional (RE), and mental health (MH). Scale scores range from 0 to 100, with higher scores indicating better health. Two overall summary scores were obtained - a Physical Component Summary score (PCS) and a Mental Component Summary score (MCS). Scores from the 8 scales, PCS and MCS were transformed to the norm-based scores using weights from U.S. general population, with 50 as the average and 10 as the standard deviation, higher scores indicating better health. For norm based scores, change from baseline were calculated for the 8 scales and the two summary scales, where change = visit value - baseline value. (NCT00773734)
Timeframe: Week 0 to Month 48

Interventionunits on a scale (Mean)
Apremilast 10mg BID-1.1
Placebo-Apremilast 20mg BID4.1
Apremilast 20mg BID-1.0
Placebo-Apremilast 30 mg BID17.6
Apremilast 30 mg BID1.2

LTE Study: Change From Baseline in the Medical Outcome Study Short Form, SF-36, Version 2; Physical Component Summary Score at 2 Years

The SF-36 was a 36-item general health status instrument and consists of 8 scales: physical function (PF), role limitations-physical (RP), vitality (VT), general health perceptions (GH), bodily pain (BP), social function (SF), role limitations-emotional (RE), and mental health (MH). Scale scores range from 0 to 100, with higher scores indicating better health. Two overall summary scores were obtained - a Physical Component Summary score (PCS) and a Mental Component Summary score (MCS). Scores from the 8 scales, PCS and MCS were transformed to the norm-based scores using weights from U.S. general population, with 50 as the average and 10 as the standard deviation, higher scores indicating better health. For norm based scores, change from baseline were calculated for the 8 scales and the two summary scales, where change = visit value - baseline value. (NCT00773734)
Timeframe: Week 0 to Month 24

Interventionunits on a scale (Mean)
Apremilast 10mg BID4.1
Placebo-Apremilast 20mg BID3.7
Apremilast 20mg BID1.0
Placebo-Apremilast 30 mg BID2.4
Apremilast 30 mg BID5.0

LTE Study: Change From Baseline in the Medical Outcome Study Short Form, SF-36, Version 2; Physical Component Summary Score at 3 Years

The SF-36 was a 36-item general health status instrument and consists of 8 scales: physical function (PF), role limitations-physical (RP), vitality (VT), general health perceptions (GH), bodily pain (BP), social function (SF), role limitations-emotional (RE), and mental health (MH). Scale scores range from 0 to 100, with higher scores indicating better health. Two overall summary scores were obtained - a Physical Component Summary score (PCS) and a Mental Component Summary score (MCS). Scores from the 8 scales, PCS and MCS were transformed to the norm-based scores using weights from U.S. general population, with 50 as the average and 10 as the standard deviation, higher scores indicating better health. For norm based scores, change from baseline were calculated for the 8 scales and the two summary scales, where change = visit value - baseline value. (NCT00773734)
Timeframe: Week 0 to Month 36

Interventionunits on a scale (Mean)
Apremilast 10mg BID6.6
Placebo-Apremilast 20mg BID1.0
Apremilast 20mg BID-0.1
Placebo-Apremilast 30 mg BID4.4
Apremilast 30 mg BID4.2

LTE Study: Change From Baseline in the Medical Outcome Study Short Form, SF-36, Version 2; Physical Component Summary Score at 4 Years

The SF-36 was a 36-item general health status instrument and consists of 8 scales: physical function (PF), role limitations-physical (RP), vitality (VT), general health perceptions (GH), bodily pain (BP), social function (SF), role limitations-emotional (RE), and mental health (MH). Scale scores range from 0 to 100, with higher scores indicating better health. Two overall summary scores were obtained - a Physical Component Summary score (PCS) and a Mental Component Summary score (MCS). Scores from the 8 scales, PCS and MCS were transformed to the norm-based scores using weights from U.S. general population, with 50 as the average and 10 as the standard deviation, higher scores indicating better health. For norm based scores, change from baseline were calculated for the 8 scales and the two summary scales, where change = visit value - baseline value. (NCT00773734)
Timeframe: Week 0 to Month 48

Interventionunits on a scale (Mean)
Apremilast 10mg BID1.4
Placebo-Apremilast 20mg BID2.0
Apremilast 20mg BID-4.1
Placebo-Apremilast 30 mg BID10.2
Apremilast 30 mg BID9.4

LTE Study: Change From Baseline in the Medical Outcome Study Short Form,SF-36, Version 2; Physical Component Summary Score at 18 Months

The SF-36 was a 36-item general health status instrument and consists of 8 scales: physical function (PF), role limitations-physical (RP), vitality (VT), general health perceptions (GH), bodily pain (BP), social function (SF), role limitations-emotional (RE), and mental health (MH). Scale scores range from 0 to 100, with higher scores indicating better health. Two overall summary scores were obtained - a Physical Component Summary score (PCS) and a Mental Component Summary score (MCS). Scores from the 8 scales, PCS and MCS were transformed to the norm-based scores using weights from U.S. general population, with 50 as the average and 10 as the standard deviation, higher scores indicating better health. For norm based scores, change from baseline were calculated for the 8 scales and the two summary scales, where change = visit value - baseline value. (NCT00773734)
Timeframe: Week 0 to Month 18

Interventionunits on a scale (Mean)
Apremilast 20mg BID10.2

LTE Study: Median Percent Change From Baseline in the Affected Body Surface Area (BSA) at 18 Months

"The overall BSA affected by psoriasis was estimated by comparison of the size of the affected area to the palm area of the participant's hand (entire palmar surface or handprint), which equates to approximately 1% of total BSA." (NCT00773734)
Timeframe: Week 0 to Month 18

Interventionpercent change (Median)
Apremilast 10mg BID-78.6
Placebo-Apremilast 20 mg BID-73.9
Apremilast 20mg BID-73.3
Placebo-Apremilast 30 mg BID-49.2
Apremilast 30 mg BID-86.4

LTE Study: Median Percent Change From Baseline in the Affected Body Surface Area (BSA) at 2 Years

"The overall BSA affected by psoriasis was estimated by comparison of the size of the affected area to the palm area of the participant's hand (entire palmar surface or handprint), which equates to approximately 1% of total BSA." (NCT00773734)
Timeframe: Week 0 to Month 24

Interventionpercent change (Median)
Apremilast 10mg BID-60.5
Placebo-Apremilast 20 mg BID-66.2
Apremilast 20mg BID-75.0
Apremilast 30 mg BID-41.5
Placebo-Apremilast 30 mg BID-77.4

LTE Study: Median Percent Change From Baseline in the Affected Body Surface Area (BSA) at 3 Years

"The overall BSA affected by psoriasis was estimated by comparison of the size of the affected area to the palm area of the participant's hand (entire palmar surface or handprint), which equates to approximately 1% of total BSA." (NCT00773734)
Timeframe: Week 0 to Month 36

Interventionpercent change (Median)
Apremilast 10mg BID-85.7
Placebo-Apremilast 20 mg BID-63.4
Apremilast 20mg BID-60.9
Placebo-Apremilast 30 mg BID-52.2
Apremilast 30 mg BID-81.0

LTE Study: Median Percent Change From Baseline in the Affected Body Surface Area (BSA) at 4 Years

"The overall BSA affected by psoriasis was estimated by comparison of the size of the affected area to the palm area of the participant's hand (entire palmar surface or handprint), which equates to approximately 1% of total BSA." (NCT00773734)
Timeframe: Week 0 to Month 48

Interventionpercent change (Median)
Apremilast 10mg BID-75.0
Placebo-Apremilast 20 mg BID-50.6
Apremilast 20mg BID-73.5
Placebo-Apremilast 30 mg BID-75.0
Apremilast 30 mg BID-91.9

LTE Study: Percent Change From Baseline in PASI Score at 18 Months

The PASI is a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling were scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions was scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The total qualitative score (sum of erythema, thickness, and scaling scores) was multiplied by the degree of involvement for each anatomic region and then multiplied by a constant. The values for each anatomic region were summed to yield the PASI score (NCT00773734)
Timeframe: Week 0 to Month 18

Interventionpercent change (Mean)
Apremilast 10mg BID-71.8
PBO-Apremilast 20mg BID-60.5
Apremilast 20mg BID-65.3
PBO-Apremilast 30 mg BID-50.0
Apremilast 30 mg BID-77.3

LTE Study: Percent Change From Baseline in PASI Score at 2 Years

The PASI is a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling were scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions was scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The total qualitative score (sum of erythema, thickness, and scaling scores) was multiplied by the degree of involvement for each anatomic region and then multiplied by a constant. The values for each anatomic region were summed to yield the PASI score (NCT00773734)
Timeframe: Week 0 to Month 24

Interventionpercent change (Mean)
Apremilast 10mg BID-57.8
PBO-Apremilast 20mg BID-64.5
Apremilast 20mg BID-65.9
PBO-Apremilast 30 mg BID-46.0
Apremilast 30 mg BID-78.4

LTE Study: Percent Change From Baseline in PASI Score at 3 Years

The PASI is a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling were scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions was scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The total qualitative score (sum of erythema, thickness, and scaling scores) was multiplied by the degree of involvement for each anatomic region and then multiplied by a constant. The values for each anatomic region were summed to yield the PASI score (NCT00773734)
Timeframe: Week 0 to Month 36

Interventionpercent change (Mean)
Apremilast 10mg BID-87.7
PBO-Apremilast 20mg BID-69.0
Apremilast 20mg BID-48.8
PBO-Apremilast 30 mg BID-48.0
Apremilast 30 mg BID-80.0

LTE Study: Percent Change From Baseline in PASI Score at 4 Years

The PASI is a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling were scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions was scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The total qualitative score (sum of erythema, thickness, and scaling scores) was multiplied by the degree of involvement for each anatomic region and then multiplied by a constant. The values for each anatomic region were summed to yield the PASI score (NCT00773734)
Timeframe: Week 0 to Month 48

Interventionpercent change (Mean)
Apremilast 10mg BID-82.5
PBO-Apremilast 20mg BID-52.0
Apremilast 20mg BID-54.3
PBO-Apremilast 30 mg BID-80.0
Apremilast 30 mg BID-85.0

LTE Study: Percent Change From Baseline in the Percent of the Affected Body Surface Area (BSA) at 18 Months

"The overall BSA affected by psoriasis was estimated by comparison of the size of the affected area to the palm area of the participant's hand (entire palmar surface or handprint), which equates to approximately 1% of total BSA." (NCT00773734)
Timeframe: Week 0 to Month 18

Interventionpercent change (Mean)
Apremilast 10mg BID-71.1
Placebo-Apremilast 20 mg BID-73.9
Apremilast 20mg BID-74.2
Placebo-Apremilast 30 mg BID-44.2
Apremilast 30 mg BID-76.7

LTE Study: Percent Change From Baseline in the Percent of the Affected Body Surface Area (BSA) at 2 Years

"The overall BSA affected by psoriasis was estimated by comparison of the size of the affected area to the palm area of the participant's hand (entire palmar surface or handprint), which equates to approximately 1% of total BSA." (NCT00773734)
Timeframe: Week 0 to Month 24

Interventionpercent change (Mean)
Apremilast 10mg BID-64.7
Placebo-Apremilast 20 mg BID-66.2
Apremilast 20mg BID-74.5
Placebo-Apremilast 30 mg BID-24.7
Apremilast 30 mg BID-74.5

LTE Study: Percent Change From Baseline in the Percent of the Affected Body Surface Area (BSA) at 3 Years

"The overall BSA affected by psoriasis was estimated by comparison of the size of the affected area to the palm area of the participant's hand (entire palmar surface or handprint), which equates to approximately 1% of total BSA." (NCT00773734)
Timeframe: Week 0 to Month 36

Interventionpercent change (Mean)
Apremilast 10mg BID-86.1
Placebo-Apremilast 20 mg BID-63.4
Apremilast 20mg BID-58.4
Placebo-Apremilast 30 mg BID-39.1
Apremilast 30 mg BID-78.5

LTE Study: Percent Change From Baseline in the Percent of the Affected Body Surface Area (BSA) at 4 Years

"The overall BSA affected by psoriasis was estimated by comparison of the size of the affected area to the palm area of the participant's hand (entire palmar surface or handprint), which equates to approximately 1% of total BSA." (NCT00773734)
Timeframe: Week 0 to Month 48

Interventionpercent change (Mean)
Apremilast 10mg BID-75.0
Placebo-Apremilast 20 mg BID-50.6
Apremilast 20mg BID-72.4
Placebo-Apremilast 30 mg BID-75.0
Apremilast 30 mg BID-86.1

LTE Study: Percentage of Participants Who Achieved a 50% Improvement (Response) in the PASI Score at 18 Months

PASI-50 response is the percentage of participants who achieved at least a 50% reduction (improvement) from baseline in PASI score. The improvement in PASI score was used as a measure of efficacy. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). (NCT00773734)
Timeframe: Week 0 to Month 18

Interventionpercentage of participants (Number)
Apremilast 10mg BID100.0
Placebo-Apremilast 20mg BID50.0
Apremilast 20mg BID70.0
Placebo-Apremilast 30 mg BID50.0
Apremilast 30 mg BID100

LTE Study: Percentage of Participants Who Achieved a 50% Improvement (Response) in the PASI Score at 2 Years

PASI-50 response is the percentage of participants who achieved at least a 50% reduction (improvement) from baseline in PASI score. The improvement in PASI score was used as a measure of efficacy. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). (NCT00773734)
Timeframe: Week 0 to Month 24

Interventionpercentage of participants (Number)
Apremilast 10mg BID60.0
Placebo-Apremilast 20mg BID50.0
Apremilast 20mg BID50.0
Placebo-Apremilast 30 mg BID25.0
Apremilast 30 mg BID90.0

LTE Study: Percentage of Participants Who Achieved a 50% Improvement (Response) in the PASI Score at 3 Years

PASI-50 response is the percentage of participants who achieved at least a 50% reduction (improvement) from baseline in PASI score. The improvement in PASI score was used as a measure of efficacy. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). (NCT00773734)
Timeframe: Week 0 to Month 36

Interventionpercentage of participants (Number)
Apremilast 10mg BID60.0
Placebo-Apremilast 20mg BID50.0
Apremilast 20mg BID30.0
Placebo-Apremilast 30 mg BID50.0
Apremilast 30 mg BID60.0

LTE Study: Percentage of Participants Who Achieved a 50% Improvement (Response) in the PASI Score at 4 Years

PASI-50 response is the percentage of participants who achieved at least a 50% reduction (improvement) from baseline in PASI score. The improvement in PASI score was used as a measure of efficacy. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). (NCT00773734)
Timeframe: Week 0 to Month 48

Interventionpercentage of participants (Number)
Apremilast 10mg BID40.0
Placebo-Apremilast 20mg BID25.0
Apremilast 20mg BID20.0
Placebo-Apremilast 30 mg BID25.0
Apremilast 30 mg BID40.0

LTE Study: Percentage of Participants Who Achieved a 75% Improvement (Response) in the PASI Score at 18 Months

PASI-75 response is the percentage of participants who achieved at least a 75% reduction (improvement) from baseline in PASI score. The improvement in PASI score was used as a measure of efficacy. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). (NCT00773734)
Timeframe: Week 0 to Month 18

Interventionpercentage of participants (Number)
Apremilast 10mg BID60.0
Placebo-Apremilast 20mg BID0.0
Apremilast 20mg BID40.0
Placebo-Apremilast 30 mg BID0.0
Apremilast 30 mg BID50.0

LTE Study: Percentage of Participants Who Achieved a 75% Improvement (Response) in the PASI Score at 2 Years

PASI-75 response is the percentage of participants who achieved at least a 75% reduction (improvement) from baseline in PASI. The improvement in PASI score was used as a measure of efficacy. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). (NCT00773734)
Timeframe: Week 0 to Month 24

Interventionpercentage of participants (Number)
Apremilast 10mg BID20.0
Placebo-Apremilast 20mg BID0.0
Apremilast 20mg BID30.0
Placebo-Apremilast 30 mg BID25.0
Apremilast 30 mg BID50.0

LTE Study: Percentage of Participants Who Achieved a 75% Improvement (Response) in the PASI Score at 3 Years

PASI-75 response is the percentage of participants who achieved at least a 75% reduction (improvement) from baseline in PASI score. The improvement in PASI score was used as a measure of efficacy. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). (NCT00773734)
Timeframe: Week 0 to Month 36

Interventionpercentage of participants (Number)
Apremilast 10mg BID60.0
Placebo-Apremilast 20mg BID25.0
Apremilast 20mg BID10.0
Placebo-Apremilast 30 mg BID0.0
Apremilast 30 mg BID30.0

LTE Study: Percentage of Participants Who Achieved a 75% Improvement (Response) in the PASI Score at 4 Years

PASI-75 response is the percentage of participants who achieved at least a 75% reduction (improvement) from baseline in PASI score. The improvement in PASI score was used as a measure of efficacy. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). (NCT00773734)
Timeframe: Week 0 to Month 48

Interventionpercentage of participants (Number)
Apremilast 10mg BID40.0
Placebo-Apremilast 20mg BID0.0
Apremilast 20mg BID0
Placebo-Apremilast 30 mg BID25.0
Apremilast 30 mg BID30.0

LTE Study: Percentage of Participants Who Achieved a 90% Improvement (Response) in the PASI Score at 18 Months

PASI-90 response is the percentage of participants who achieved at least a 90% reduction (improvement) from baseline in PASI score at Week 76 of the long-term extension study. The improvement in PASI score was used as a measure of efficacy. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). (NCT00773734)
Timeframe: Week 0 to Month 18

Interventionpercentage of participants (Number)
Apremilast 10mg BID0.0
Placebo-Apremilast 20mg BID0.0
Apremilast 20mg BID10.0
Placebo-Apremilast 30 mg BID0.0
Apremilast 30 mg BID30.0

LTE Study: Percentage of Participants Who Achieved a 90% Improvement (Response) in the PASI Score at 2 Years

PASI-90 response is the percentage of participants who achieved at least a 90% reduction (improvement) from baseline in PASI score at Week 100 of the extension study. The improvement in PASI score was used as a measure of efficacy. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). (NCT00773734)
Timeframe: Week 0 to Month 24

Interventionpercentage of participants (Number)
Apremilast 10mg BID0.0
Placebo-Apremilast 20mg BID0
Apremilast 20mg BID10.0
Placebo-Apremilast 30 mg BID0.0
Apremilast 30 mg BID30.0

LTE Study: Percentage of Participants Who Achieved a 90% Improvement (Response) in the PASI Score at 3 Years

PASI-90 response is the percentage of participants who achieved at least a 90% reduction (improvement) from baseline in PASI score at Week 148 of the extension study. The improvement in PASI score was used as a measure of efficacy. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). (NCT00773734)
Timeframe: Week 0 to Month 36

Interventionpercentage of participants (Number)
Apremilast 10mg BID20.0
Placebo-Apremilast 20mg BID0.0
Apremilast 20mg BID10.0
Placebo-Apremilast 30 mg BID0.0
Apremilast 30 mg BID20.0

LTE Study: Percentage of Participants Who Achieved a 90% Improvement (Response) in the PASI Score at 4 Years

PASI-90 response is the percentage of participants who achieved at least a 90% reduction (improvement) from baseline in PASI score at Week 196 of the extension study. The improvement in PASI score was used as a measure of efficacy. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). (NCT00773734)
Timeframe: Week 0 to Month 48

Interventionpercentage of participants (Number)
Apremilast 10mg BID0.0
Placebo-Apremilast 20mg BID0.0
Apremilast 20mg BID0.0
Placebo-Apremilast 30 mg BID0.0
Apremilast 30 mg BID20.0

LTE Study: Percentage of Participants Who Achieved a Static Physician Global Assessment (sPGA) Score of 0 or 1 at 18 Months

The sPGA was a measure of psoriasis disease severity at the time of evaluation by the investigator. It does not compare assessments across visits or rely on investigator recall of prior disease severity. The sPGA was a 6-point scale ranging from 0 (clear, except for residual discoloration) to 5 (severe; majority of plaques have severe thickness, erythema, and scaling). The investigator examined all of the lesions on the participant and assigned a score ranging from 0 to 5 for thickness, erythema and degree of scaling . Scores for thickness, erythema and scaling are then summed and the mean of these 3 scores equaled the overall sPGA score. Fractional values for the sPGA were rounded to the next highest integer (eg, a score of 3.5 was rounded to 4, 3.4 was rounded to 3). A lower sPGA score was associated with less severe disease (NCT00773734)
Timeframe: Week 0 to Month 18

Interventionpercentage of participants (Number)
Apremilast 10mg BID60.0
Placebo-Apremilast 20 mg BID0.0
Apremilast 20mg BID20.0
Placebo-Apremilast 30 mg BID25.0
Apremilast 30 mg BID60.0

LTE Study: Percentage of Participants Who Achieved a Static Physician Global Assessment (sPGA) Score of 0 or 1 at 2 Years

The sPGA was a measure of psoriasis disease severity at the time of evaluation by the investigator. It does not compare assessments across visits or rely on investigator recall of prior disease severity. The sPGA was a 6-point scale ranging from 0 (clear, except for residual discoloration) to 5 (severe; majority of plaques have severe thickness, erythema, and scaling). The investigator examined all of the lesions on the participant and assigned a score ranging from 0 to 5 for thickness, erythema and degree of scaling . Scores for thickness, erythema and scaling are then summed and the mean of these 3 scores equaled the overall sPGA score. Fractional values for the sPGA were rounded to the next highest integer (eg, a score of 3.5 was rounded to 4, 3.4 was rounded to 3). A lower sPGA score was associated with less severe disease (NCT00773734)
Timeframe: Week 0 to Month 24

Interventionpercentage of participants (Number)
Apremilast 10mg BID20.0
Placebo-Apremilast 20 mg BID0.00
Apremilast 20mg BID10.0
Placebo-Apremilast 30 mg BID25.0
Apremilast 30 mg BID40.0

LTE Study: Percentage of Participants Who Achieved a Static Physician Global Assessment (sPGA) Score of 0 or 1 at 3 Years

The sPGA was a measure of psoriasis disease severity at the time of evaluation by the investigator. It does not compare assessments across visits or rely on investigator recall of prior disease severity. The sPGA was a 6-point scale ranging from 0 (clear, except for residual discoloration) to 5 (severe; majority of plaques have severe thickness, erythema, and scaling). The investigator examined all of the lesions on the participant and assigned a score ranging from 0 to 5 for thickness, erythema and degree of scaling . Scores for thickness, erythema and scaling are then summed and the mean of these 3 scores equaled the overall sPGA score. Fractional values for the sPGA were rounded to the next highest integer (eg, a score of 3.5 was rounded to 4, 3.4 was rounded to 3). A lower sPGA score was associated with less severe disease (NCT00773734)
Timeframe: Week 0 and month 36

Interventionpercentage of participants (Number)
Apremilast 10mg BID60.0
Placebo-Apremilast 20 mg BID0.0
Apremilast 20mg BID0
Placebo-Apremilast 30 mg BID25.0
Apremilast 30 mg BID30.0

LTE Study: Percentage of Participants Who Achieved a Static Physician Global Assessment (sPGA) Score of 0 or 1 at 4 Years

The sPGA was a measure of psoriasis disease severity at the time of evaluation by the investigator. It does not compare assessments across visits or rely on investigator recall of prior disease severity. The sPGA was a 6-point scale ranging from 0 (clear, except for residual discoloration) to 5 (severe; majority of plaques have severe thickness, erythema, and scaling). The investigator examined all of the lesions on the participant and assigned a score ranging from 0 to 5 for thickness, erythema and degree of scaling . Scores for thickness, erythema and scaling are then summed and the mean of these 3 scores equaled the overall sPGA score. Fractional values for the sPGA were rounded to the next highest integer (eg, a score of 3.5 was rounded to 4, 3.4 was rounded to 3). A lower sPGA score was associated with less severe disease (NCT00773734)
Timeframe: Week 0 to Month 48

Interventionpercentage of participants (Number)
Apremilast 10mg BID20.0
Placebo-Apremilast 20 mg BID0.0
Apremilast 20mg BID0.0
Placebo-Apremilast 30 mg BID25.0
Apremilast 30 mg BID30.0

Time to Loss of 50% of the PASI Response During the Observational Follow-up Phase Relative to the End of Treatment (Participants Who Had at Least a PASI-50 Response at the End of Treatment Phase)

Time to loss of response was modified to be 50% loss in the PASI response observed at the end of treatment for participants who achieved at least a PASI-50 at the end of treatment. This definition was changed since participants may have already lost their maximal PASI response prior to enrollment into the Observation Follow-up Phase. Included all participants that enrolled into the observational follow-up phase after the treatment phase. (NCT00773734)
Timeframe: Up to 4 weeks after the last dose

Interventionweeks (Median)
Apremilast 10mg BIDNA
Apremilast 20mg BIDNA
Apremilast 30 mg BIDNA
Placebo-Apremilast 20mg BIDNA
Placebo-Apremilast 30 mg BID5.3

Number of Participants With Treatment Emergent Adverse Events (TEAE) in the Apremilast Exposure Period

An AE was any noxious, unintended, or untoward medical occurrence, that may appear or worsen in a participant during the course of study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the participant's health, including laboratory test values regardless of etiology. Any worsening (ie, any clinically significant adverse change in the frequency or intensity of a preexisting condition) was considered an AE. A serious AE (SAE) is any untoward adverse event that is fatal, life-threatening, results in persistent or significant disability or incapacity, requires or prolongs existing in-patient hospitalization, is a congenital anomaly/birth defect, or is a condition that may jeopardize the patient or may require intervention to prevent one of the outcomes listed above. An AE is a treatment emergent AE if the AE start date is on or after the date of the first dose of study drug and no later than 28 days after the last dose. (NCT00773734)
Timeframe: Week 0 to 6 years of study treatment; maximum duration of exposure was 314.6 weeks

,,
Interventionparticipants (Number)
Any treatment emergent AEAny drug-related TEAEAny severe TEAEAny serious TEAEAny serious drug-related≥ 1 TEAE leading to drug interruption≥ 1 TEAE leading to drug withdrawal≥ 1 TEAE leading to death
Apremilast 10mg BID6723420350
Apremilast 20mg BID9732109111110
Apremilast 30 mg BID11146146010160

Number of Participants With Treatment Emergent Adverse Events (TEAE) in the Apremilast Exposure Period

An AE was any noxious, unintended, or untoward medical occurrence, that may appear or worsen in a participant during the course of study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the participant's health, including laboratory test values regardless of etiology. Any worsening (ie, any clinically significant adverse change in the frequency or intensity of a preexisting condition) was considered an AE. A serious AE (SAE) is any untoward adverse event that is fatal, life-threatening, results in persistent or significant disability or incapacity, requires or prolongs existing in-patient hospitalization, is a congenital anomaly/birth defect, or is a condition that may jeopardize the patient or may require intervention to prevent one of the outcomes listed above. An AE is a treatment emergent AE if the AE start date is on or after the date of the first dose of study drug and no later than 28 days after the last dose. (NCT00773734)
Timeframe: Week 0-88; up to data cut off of 21 July 2011

,,
Interventionparticipants (Number)
Any treatment emergent AEAny drug-related TEAEAny severe TEAEAny serious TEAEAny serious drug-related≥ 1 TEAE leading to drug interruption≥ 1 TEAE leading to drug withdrawal≥ 1 TEAE leading to death
Apremilast 10mg BID6723310350
Apremilast 20mg BID973198111110
Apremilast 30 mg BID1104513609150

Number of Participants With Treatment Emergent Adverse Events (TEAE) in the Placebo Controlled Phase

An AE was any noxious, unintended, or untoward medical occurrence, that may appear or worsen in a participant during the course of study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the participant's health, including laboratory test values regardless of etiology. Any worsening (ie, any clinically significant adverse change in the frequency or intensity of a preexisting condition) was considered an AE. A serious AE (SAE) is any untoward adverse event that is fatal, life-threatening, results in persistent or significant disability or incapacity, requires or prolongs existing in-patient hospitalization, is a congenital anomaly/birth defect, or is a condition that may jeopardize the patient or may require intervention to prevent one of the outcomes listed above. An AE is a treatment emergent AE if the AE start date is on or after the date of the first dose of study drug and no later than 28 days after the last dose. (NCT00773734)
Timeframe: Week 0 to Week 16; up to data cut off of 21 July 2011

,,,
Interventionparticipants (Number)
Any treatment emergent AEAny drug-related TEAEAny severe TEAEAny serious TEAEAny serious drug-related≥ 1 TEAE leading to drug interruption≥ 1 TEAE leading to drug withdrawal≥ 1 TEAE leading to death
Apremilast 10mg BID5920100320
Apremilast 20mg BID6723530380
Apremilast 30 mg BID72325406120
Placebo5711320451

Change From Baseline in Dermatological Life Quality Index (DLQI) Total Score at Week 16

"DLQI is questionnaire for use in a dermatology clinical setting to assess limitations related to the impact of skin disease. The instrument contains ten items dealing with the participant's skin. With the exception of Item Number 7, the participant responds on a four-point scale, ranging from Very Much (score 3) to Not at All or Not relevant (score 0). Item Number 7 is a multi-part item, the first part of which ascertains whether the participant's skin prevented them from working or studying (Yes or No, scores 3 or 0 respectively), and if No, then the subject is asked how much of a problem the skin has been at work or study over the past week, with response alternatives being A lot, A little, or Not at all (scores 2, 1, or 0 respectively). The DLQI total score was derived by summing all item scores, and has a possible range of 0 to 30, with 30 corresponding to the worst quality of life, and 0 corresponding to the best." (NCT03123471)
Timeframe: Baseline to Week 16

InterventionUnits on a Scale (Least Squares Mean)
Placebo/Apremilast-3.8
Apremilast-6.7

Percentage of Participants With ≥ 4-Point Reduction (Improvement) From Baseline in the Scalp Itch Numeric Rating Score (NRS) at Week 16

"The scalp itch NRS is a 11-point scale to assess scalp itch. The scale ranges from 0-10, where 0 represents no itch, and 10 represents the worst imaginable itch." (NCT03123471)
Timeframe: Baseline to Week 16

InterventionPercentage of Participants (Number)
Placebo/Apremilast21.1
Apremilast47.1

Percentage of Participants With ≥ 4-Point Reduction (Improvement) From Baseline in the Whole Body Itch Numeric Rating Score at Week 16

"The Whole Body Itch NRS scale is an 11-point scale to assess whole body itch. The scale ranges from 0-10, where 0 represents no itch, and 10 represents the worst imaginable itch, and a 4-point change from baseline was shown to be optimal for demonstrating a level of clinically meaningful improvement in itch severity. NRS response was defined as a ≥ 4-point reduction (improvement) from baseline." (NCT03123471)
Timeframe: Baseline to Week 16

InterventionPercentage of Participants (Number)
Placebo/Apremilast22.5
Apremilast45.5

Percentage of Participants With Scalp Physician Global Assessment (ScPGA) Score of Clear (0) or Almost Clear (1) With at Least a 2-Point Reduction From Baseline

The ScPGA is a measurement of overall scalp involvement by the investigator at the time of evaluation. The ScPGA is a 5-point scale ranging from 0 (clear) to 4 (severe), incorporating an assessment of the severity of the 3 primary signs of the disease: erythema, scaling, and plaque elevation. When making the assessment of overall scalp severity, the investigator factored in areas that had already been cleared (ie, had scores of 0), not limited to the evaluation of remaining lesions for severity; consequently, the severity of each sign was averaged across all areas of involvement, including cleared lesions. (NCT03123471)
Timeframe: Baseline to Week 16

InterventionPercentage of Participants (Number)
Placebo/Apremilast13.7
Apremilast43.3

Number of Participants With Treatment Emergent Adverse Events (TEAE) During the Placebo-Controlled Phase

A TEAE is an AE with a start date on or after the date of the first dose of study drug and no later than 28 days after the last dose of study drug. A serious AE (SAE) is any untoward AE that is fatal, life-threatening, results in persistent or significant disability or incapacity, requires or prolongs existing in-patient hospitalization, is a congenital anomaly/birth defect, or is a condition that may jeopardize or may require intervention to prevent one of the outcomes above. The severity of AEs was assessed based on the following scale: Mild = asymptomatic or mild symptoms, clinical or diagnostic observations only; Moderate = symptoms cause moderate discomfort; Severe = could be non-serious or serious) = symptoms causing severe pain discomfort. (NCT03123471)
Timeframe: Week 0 to Week 16; mean duration of exposure was 14.5 weeks and 14.6 weeks for participants randomized to placebo and apremilast respectively.

,
InterventionParticipants (Count of Participants)
Any TEAEAny Drug-related TEAEAny Severe TEAEAny Serious TEAEAny TEAE Leading to Drug InterruptionAny TEAE Leading to Drug Withdrawal
Apremilast1359952911
Placebo/Apremilast52222143

Number of Participants With Treatment Emergent Adverse Events During the Apremilast-Exposure Period

The apremilast-exposure period started on the date of the first dose of apremilast (Week 0 for participants originally randomized to apremilast or Week 16 for participants originally randomized to placebo) to the last dose of apremilast. A TEAE is an AE with a start date on or after the date of the first dose of study drug and no later than 28 days after the last dose of study drug. A serious AE (SAE) is any untoward AE that is fatal, life-threatening, results in persistent or significant disability or incapacity, requires or prolongs existing in-patient hospitalization, is a congenital anomaly/birth defect, or is a condition that may jeopardize or may require intervention to prevent one of the outcomes above. The severity of AEs was assessed based on the following scale: Mild = asymptomatic or mild symptoms, clinical or diagnostic observations only; Moderate = symptoms cause moderate discomfort; Severe = could be non-serious or serious) = symptoms causing severe pain discomfort. (NCT03123471)
Timeframe: Week 0 to 32;

,
InterventionParticipants (Count of Participants)
Any TEAEAny Drug-related TEAEAny Severe TEAEAny Serious TEAEAny Serious TEAE Drug Related TEAEAny TEAE Leading to Drug InterruptionAny TEAE Leading to Drug WithdrawalDeaths
Apremilast14410386313150
Placebo/Apremilast3517210210

Number of Participants With Treatment Emergent Adverse Events During the Apremilast-Extension Phase

A TEAE is an AE with a start date on or after the date of the first dose of study drug and no later than 28 days after the last dose of study drug. A serious AE (SAE) is any untoward AE that is fatal, life-threatening, results in persistent or significant disability or incapacity, requires or prolongs existing in-patient hospitalization, is a congenital anomaly/birth defect, or is a condition that may jeopardize or may require intervention to prevent one of the outcomes above. The severity of AEs was assessed based on the following scale: Mild = asymptomatic or mild symptoms, clinical or diagnostic observations only; Moderate = symptoms cause moderate discomfort; Severe = could be non-serious or serious) = symptoms causing severe pain discomfort. (NCT03123471)
Timeframe: Weeks 16 to Week 32; the mean treatment duration was 14.6 weeks and 15.3 weeks in the APR 30/APR 30 BID and placebo/APR 30 BID arms, respectively

,
InterventionParticipants (Count of Participants)
Any TEAEAny Drug-related TEAEAny Severe TEAEAny Serious TEAEAny TEAE Leading to Drug InterruptionAny TEAE Leading to Drug WithdrawalDeaths
Apremilast661745440
Placebo/Apremilast351721210

Percentage of Participants With ≥ 4-Point Reduction (Improvement) From Baseline in the Scalp Itch NRS Score by Visit in the Placebo-Controlled Phase

"The scalp itch NRS is a 11-point scale to assess scalp itch. The scale ranges from 0-10, where 0 represents no itch, and 10 represents the worst imaginable itch." (NCT03123471)
Timeframe: Baseline to Weeks 2, 4, 8 and 12

,
InterventionPercentage of Participants (Number)
Week 2Week 4Week 8Week 12
Apremilast26.137.845.646.5
Placebo/Apremilast11.516.523.719.6

Percentage of Participants With ≥ 4-Point Reduction (Improvement) From Baseline in the Whole Body Itch NRS Score by Visit in the Placebo-Controlled Phase

"The Whole Body Itch NRS scale is a 11-point scale to assess whole body itch. The scale ranges from 0-10, where 0 represents no itch, and 10 represents the worst imaginable itch, and a 4-point change from baseline was shown to be optimal for demonstrating a level of clinically meaningful improvement in itch severity." (NCT03123471)
Timeframe: Baseline to Weeks 2, 4, 6, 8 and 12

,
InterventionPercentage of Participants (Number)
Week 2Week 4Week 8Week 12
Apremilast20.532.339.847.0
Placebo/Apremilast3.510.119.726.3

Percentage of Participants Who Were Lice-Free by Day 2 That Were Maintained Through Day 15 Post-treatment With Either Ivermectin or Placebo (Vehicle Control)

Live lice eradication was assessed by visual checks of hair and scalp on Days 1, 2 and 8 and by visual checks and counting both live and dead lice from rinse water on Day 15. Eradication was defined as cessation of motility (antennae and leg movement) in all lice. (NCT00857948)
Timeframe: Day 1 through Day 15 post-application

InterventionPercent of participants (Number)
0.15% Ivermectin56
0.25% Ivermectin50
0.50% Ivermectin74
Placebo9

Level of Live Lice Infestation at Different Time Points Post-Treatment With Either Ivermectin or Placebo (Vehicle Control)

The severity of lice infestation was determined by visual checks of hair and scalp. Severity was rated as None: no live lice; Mild: 1 to 5 live lice; Moderate: 6 to 10 live lice; Severe: 11 to 20 live lice; or Very severe > 20 live lice. (NCT00857948)
Timeframe: Day 1 through Day 15 post-application

,,,
InterventionPercent of participants (Number)
Day 1: 2 Hours Post Dose: NoneDay 1: 2 Hours Post Dose: MildDay 1: 2 Hours Post Dose: ModerateDay 1: 6 Hours Post Dose: NoneDay 1: 6 Hours Post Dose: MildDay 1: 6 Hours Post Dose: ModerateDay 2: NoneDay 2: MildDay 2: ModerateDay 8: Treatment Failure Day 2Day 8: NoneDay 8: MildDay 8: ModerateDay 8: SevereDay 15: Treatment Failure Day 8Day 15: NoneDay 15: Mild
0.15% Ivermectin3350175039118317017721100335611
0.25% Ivermectin445606733094606726611285617
0.50% Ivermectin32635583759550584505167411
Placebo22651330619177848399009190

Number of Participants Reporting Treatment-Emergent Adverse Events Post-treatment With Either Ivermectin or Placebo (Vehicle Control).

(NCT00857948)
Timeframe: Day 1 up to Day 28 post-application

,,,
InterventionParticipants (Number)
ConjunctivitisSevere ConjunctivitisEye PruritusSevere Eye PruritusErythemaSevere ErythemaFolliculitisSevere FolliculitisPruritusSevere PruritusSkin IrritationSevere Skin Irritation
0.15% Ivermectin001000005000
0.25% Ivermectin000000101000
0.50% Ivermectin100010003000
Placebo000030101010

Percentage of Index Participants Who Were Lice-Free at Different Time Points Post-treatment With Either Ivermectin or Placebo (Vehicle Control)

Live lice eradication was assessed on Days 1, 2, and 8 by visual checks of hair and scalp. Eradication was defined as cessation of motility (antennae and leg movement) in all lice. (NCT00857948)
Timeframe: Day 1 through Day 8 post-application

,,,
InterventionPercent of participants (Number)
Day 1: 2 hours post-applicationDay 1: 6 hours post-applicationDay 2Day 8
0.15% Ivermectin33508367
0.25% Ivermectin44679472
0.50% Ivermectin32589584
Placebo2230179

Reviews

9 reviews available for salicylic acid and Pruritus

ArticleYear
The management of chronic pruritus in the elderly.
    Skin therapy letter, 2010, Volume: 15, Issue:8

    Topics: Administration, Oral; Administration, Topical; Aged; Antipruritics; Cannabinoids; Capsaicin; Central

2010
Scalp dysesthesia: a neuropathic phenomenon.
    Journal of the European Academy of Dermatology and Venereology : JEADV, 2022, Volume: 36, Issue:6

    Topics: Aged; COVID-19; Female; Humans; Paresthesia; Pruritus; Scalp; Skin Diseases

2022
[Tinea capitis in children is an overlooked disease].
    Ugeskrift for laeger, 2020, 03-09, Volume: 182, Issue:11

    Topics: Alopecia; Antifungal Agents; Child; Humans; Pain; Pruritus; Scalp; Tinea Capitis

2020
Multiple Warty Dyskeratomas With Severe Pruritus: A Case Report and Literature Review.
    The American Journal of dermatopathology, 2018, Volume: 40, Issue:3

    Topics: Female; Head and Neck Neoplasms; Humans; Middle Aged; Pruritus; Scalp; Skin Neoplasms

2018
Scalp Pruritus: Review of the Pathogenesis, Diagnosis, and Management.
    BioMed research international, 2019, Volume: 2019

    Topics: Animals; Humans; Pruritus; Quality of Life; Scalp; Skin

2019
Neurocutaneous disease: Neurocutaneous dysesthesias.
    Journal of the American Academy of Dermatology, 2016, Volume: 74, Issue:2

    Topics: Facial Dermatoses; Femoral Neuropathy; Humans; Nerve Compression Syndromes; Paresthesia; Pruritus; S

2016
The itchy scalp--scratching for an explanation.
    Experimental dermatology, 2011, Volume: 20, Issue:12

    Topics: Animals; Humans; Pruritus; Scalp; Sebum

2011
[Paroxismal reactions of the scalp].
    Revue medicale de Liege, 2004, Volume: 59, Issue:4

    Topics: Acute Disease; Adult; Alopecia; Dermatitis, Seborrheic; Female; Humans; Lice Infestations; Male; Pos

2004
The itchy patient. A practical approach.
    Primary care, 1983, Volume: 10, Issue:3

    Topics: Cholestasis; Drug-Related Side Effects and Adverse Reactions; Endocrine System Diseases; Female; Hem

1983

Trials

14 trials available for salicylic acid and Pruritus

ArticleYear
Maintenance effect of a once-weekly regimen of a Selenium Disulfide-based shampoo in moderate-to-severe scalp seborrheic dermatitis after initial treatment with topical corticosteroid/salicylic acid.
    European journal of dermatology : EJD, 2023, Mar-01, Volume: 33, Issue:S1

    Topics: Adrenal Cortex Hormones; Adult; Dandruff; Dermatitis, Seborrheic; Double-Blind Method; Humans; Pruri

2023
Randomized trial comparing a chemical peel containing a lipophilic hydroxy acid derivative of salicylic acid with a salicylic acid peel in subjects with comedonal acne.
    Journal of cosmetic dermatology, 2011, Volume: 10, Issue:3

    Topics: Acne Vulgaris; Administration, Topical; Adult; Chemexfoliation; Erythema; Face; Female; Humans; Kera

2011
Single-center, open-label study of a proprietary topical 0.5% salicylic acid-based treatment regimen containing sandalwood oil in adolescents and adults with mild to moderate acne.
    Journal of drugs in dermatology : JDD, 2012, Volume: 11, Issue:12

    Topics: Acne Vulgaris; Administration, Topical; Adolescent; Adult; Drug Combinations; Endpoint Determination

2012
Calcipotriol solution for the treatment of scalp psoriasis: evaluation of efficacy, safety and acceptance in 3,396 patients.
    Dermatology (Basel, Switzerland), 2001, Volume: 203, Issue:2

    Topics: Adult; Calcitriol; Cohort Studies; Combined Modality Therapy; Dermatologic Agents; Drug Therapy, Com

2001
Saccharide isomerate ameliorates cosmetic scalp conditions in a Chinese study population.
    Journal of cosmetic dermatology, 2023, Volume: 22, Issue:1

    Topics: Adult; Dandruff; Humans; Pruritus; Scalp; Skin

2023
TRPM8 agonist (cryosim-1) gel for scalp itch: a randomised, vehicle-controlled clinical trial.
    Journal of the European Academy of Dermatology and Venereology : JEADV, 2022, Volume: 36, Issue:7

    Topics: Humans; Membrane Proteins; Pruritus; Scalp; TRPM Cation Channels

2022
Clinical evaluation of paraprobiotic-associated Bifidobacterium lactis CCT 7858 anti-dandruff shampoo efficacy: A randomized placebo-controlled clinical trial.
    International journal of cosmetic science, 2023, Volume: 45, Issue:5

    Topics: Bifidobacterium animalis; Dandruff; Hair Preparations; Humans; Pruritus; Scalp; Skin

2023
Pharmacokinetics of ingenol mebutate gel under maximum use conditions in large treatment areas.
    The Journal of dermatological treatment, 2018, Volume: 29, Issue:1

    Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Area Under Curve; Arm; Diterpenes; Face; Female;

2018
Safety and Efficacy of Escalating Doses of Ingenol Mebutate for Field Treatment of Actinic Keratosis on the Full Face, Full Balding Scalp, or Chest.
    Journal of drugs in dermatology : JDD, 2017, May-01, Volume: 16, Issue:5

    Topics: Administration, Topical; Aged; Diterpenes; Dose-Response Relationship, Drug; Face; Female; Humans; K

2017
Secukinumab improves scalp pain, itching, scaling and quality of life in patients with moderate-to-severe scalp psoriasis.
    The Journal of dermatological treatment, 2017, Volume: 28, Issue:8

    Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Double-Blind Method; Female; Human

2017
Efficacy of a new tonic containing urea, lactate, polidocanol, and glycyrrhiza inflata root extract in the treatment of a dry, itchy, and subclinically inflamed scalp.
    Skin pharmacology and physiology, 2013, Volume: 26, Issue:2

    Topics: Chalcones; Cytokines; Glycyrrhiza; Humans; Lactic Acid; Lipid Metabolism; Plant Extracts; Plant Root

2013
Scalp stratum corneum histamine levels: novel sampling method reveals association with itch resolution in dandruff/seborrhoeic dermatitis treatment.
    Acta dermato-venereologica, 2011, Volume: 91, Issue:4

    Topics: Administration, Topical; Adult; Analysis of Variance; Antipruritics; Biomarkers; Chromatography, Hig

2011
Assessment of the safety and efficacy of three concentrations of topical ivermectin lotion as a treatment for head lice infestation.
    International journal of dermatology, 2013, Volume: 52, Issue:1

    Topics: Administration, Topical; Adolescent; Adult; Animals; Child; Child, Preschool; Dose-Response Relation

2013
A national double-blind clinical trial of a new corticosteroid lotion: a 12-investigator cooperative analysis.
    Current therapeutic research, clinical and experimental, 1972, Volume: 14, Issue:9

    Topics: 1-Propanol; Adolescent; Adult; Aged; Betamethasone; Child; Child, Preschool; Clinical Trials as Topi

1972

Other Studies

43 other studies available for salicylic acid and Pruritus

ArticleYear
The effect of topically applied salicylic compounds on serotonin-induced scratching behaviour in hairless rats.
    Experimental dermatology, 2002, Volume: 11, Issue:4

    Topics: Administration, Topical; Animals; Antipruritics; Female; Pruritus; Rats; Rats, Mutant Strains; Salic

2002
SEBORRHEA, SEBORRHEIC DERMATITIS AND THE SEBORRHEID REACTION.
    Medical science, 1964, Volume: 15

    Topics: Adrenal Cortex Hormones; Child; Clioquinol; Coal Tar; Dermatitis; Dermatitis, Seborrheic; Dermatolog

1964
[A new type of treatment of pruritic dermatoses].
    Der Landarzt, 1961, Dec-20, Volume: 37

    Topics: Dermatology; Humans; Pruritus; Salicylic Acid; Skin Diseases

1961
Pruritus: Diagnosis and Management.
    American family physician, 2022, 01-01, Volume: 105, Issue:1

    Topics: Administration, Topical; Adrenal Cortex Hormones; Aged; Blood Cell Count; Blood Sedimentation; Blood

2022
Localized alopecia with itching on the scalp.
    Clinical and experimental dermatology, 2022, Volume: 47, Issue:9

    Topics: Alopecia; Dermoscopy; Diagnosis, Differential; Humans; Pruritus; Scalp; Scalp Dermatoses

2022
Microbiota profiling on itchy scalp with undetermined origin.
    Archives of microbiology, 2022, Jul-01, Volume: 204, Issue:7

    Topics: Female; Humans; Microbiota; Pruritus; RNA, Ribosomal, 16S; Scalp; Skin

2022
Prospective Observational Evaluation of Fixed Combination Calcipotriol/Betamethasone Aerosol Foam (Enstilar®) in the Management of Psoriasis with Scalp Involvement in Everyday Clinical Practice (the CAPITIS Study).
    Dermatology (Basel, Switzerland), 2023, Volume: 239, Issue:2

    Topics: Adult; Aerosols; Betamethasone; Dermatologic Agents; Drug Combinations; Humans; Prospective Studies;

2023
Persistent itching of the eyelids and scalp.
    BMJ (Clinical research ed.), 2022, 09-08, Volume: 378

    Topics: Eyelids; Humans; Pruritus; Scalp

2022
Neuroimmune Mediators of Pruritus in Hispanic Scalp Psoriatic Itch.
    Acta dermato-venereologica, 2023, Mar-23, Volume: 103

    Topics: Hispanic or Latino; Humans; Pruritus; Psoriasis; Scalp; Substance P

2023
Alopecia in Patients with Collagen VI-Related Myopathies: A Novel/Unrecognized Scalp Phenotype.
    International journal of molecular sciences, 2023, Apr-03, Volume: 24, Issue:7

    Topics: Alopecia; Collagen; Folliculitis; Humans; Muscular Diseases; Phenotype; Pruritus; Scalp

2023
Treatment of scalp dysesthesia utilising simple exercises and stretches: A pilot study.
    The Australasian journal of dermatology, 2018, Volume: 59, Issue:4

    Topics: Adolescent; Adult; Aged; Cervical Vertebrae; Exercise Therapy; Female; Humans; Male; Middle Aged; Mu

2018
Trichostasis spinulosa arising in isolated collagenoma of the scalp.
    European journal of dermatology : EJD, 2018, Aug-01, Volume: 28, Issue:4

    Topics: Alopecia; Child; Female; Hair Diseases; Head and Neck Neoplasms; Humans; Keratosis; Nevus; Pruritus;

2018
A Lesion on the Scalp.
    JAMA oncology, 2019, 01-01, Volume: 5, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Head and Neck Neoplasms; Humans; Lymphoma, Fol

2019
Qualitative analysis and reproducibility assessment of the Scalp Itch Numeric Rating Scale among patients with moderate to severe plaque psoriasis of the scalp.
    The Journal of dermatological treatment, 2019, Volume: 30, Issue:8

    Topics: Adult; Aged; Cross-Sectional Studies; Female; Humans; Interviews as Topic; Male; Middle Aged; Prurit

2019
Qualitative analysis and reproducibility assessment of the Scalp Itch Numeric Rating Scale among patients with moderate to severe plaque psoriasis of the scalp.
    The Journal of dermatological treatment, 2019, Volume: 30, Issue:8

    Topics: Adult; Aged; Cross-Sectional Studies; Female; Humans; Interviews as Topic; Male; Middle Aged; Prurit

2019
Qualitative analysis and reproducibility assessment of the Scalp Itch Numeric Rating Scale among patients with moderate to severe plaque psoriasis of the scalp.
    The Journal of dermatological treatment, 2019, Volume: 30, Issue:8

    Topics: Adult; Aged; Cross-Sectional Studies; Female; Humans; Interviews as Topic; Male; Middle Aged; Prurit

2019
Qualitative analysis and reproducibility assessment of the Scalp Itch Numeric Rating Scale among patients with moderate to severe plaque psoriasis of the scalp.
    The Journal of dermatological treatment, 2019, Volume: 30, Issue:8

    Topics: Adult; Aged; Cross-Sectional Studies; Female; Humans; Interviews as Topic; Male; Middle Aged; Prurit

2019
Refractory Cutaneous Dermatomyositis With Severe Scalp Pruritus Responsive to Apremilast.
    Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2021, Dec-01, Volume: 27, Issue:8S

    Topics: Dermatomyositis; Female; Humans; Immunomodulating Agents; Immunosuppressive Agents; Pruritus; Scalp;

2021
Evaluation of factors triggering sensitive scalp in Korean adult women.
    Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI), 2019, Volume: 25, Issue:6

    Topics: Adult; Body Temperature; Female; Humans; Middle Aged; Pruritus; Republic of Korea; Scalp; Skin Disea

2019
Women with scalp dysesthesia treated with pregabalin.
    International journal of dermatology, 2013, Volume: 52, Issue:11

    Topics: Adult; Analgesics; Female; gamma-Aminobutyric Acid; Humans; Pain; Paresthesia; Pregabalin; Pruritus;

2013
Clinical and histopathological features of itch in patients with alopecia areata.
    Acta dermato-venereologica, 2013, Sep-04, Volume: 93, Issue:5

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alopecia Areata; Arachidonate 5-Lipoxygenase; Biopsy; Ca

2013
Severe facial swelling in a pregnant woman after using hair dye.
    BMJ case reports, 2014, Mar-31, Volume: 2014

    Topics: Adult; Edema; Face; Female; Hair Dyes; Humans; Hypersensitivity, Delayed; Pregnancy; Pregnancy Compl

2014
Trigeminal trophic syndrome with histopathologic correlation.
    Cutis, 2015, Volume: 95, Issue:3

    Topics: Biopsy; Female; Herpes Zoster; Humans; Middle Aged; Nasal Cavity; Pain; Pruritus; Scalp; Syndrome; T

2015
Cronkhite-Canada syndrome: A rare disease presenting with dermatological and gastrointestinal manifestations.
    The Australasian journal of dermatology, 2016, Volume: 57, Issue:2

    Topics: Abdominal Pain; Aged; Alopecia; Anorexia; Diarrhea; Female; Humans; Intestinal Polyposis; Lethargy;

2016
Acute alopecia with underlying pruritic erythema.
    Journal of the American Academy of Dermatology, 2015, Volume: 73, Issue:5

    Topics: Adult; Alopecia; Erythema; Facial Dermatoses; Facial Neoplasms; Forehead; Head and Neck Neoplasms; H

2015
Multiple eruptive milia on scalp.
    Journal of the European Academy of Dermatology and Venereology : JEADV, 2016, Volume: 30, Issue:11

    Topics: Adolescent; Aged; Child; Child, Preschool; Female; Humans; Keratosis; Male; Middle Aged; Pruritus; S

2016
Tick Bite Alopecia: A Report and Review.
    The American Journal of dermatopathology, 2016, Volume: 38, Issue:11

    Topics: Adolescent; Alopecia; Biopsy; Child; Child, Preschool; Female; Humans; Male; Mucinosis, Follicular;

2016
Physiological and microbiological verification of the benefit of hair washing in patients with skin conditions of the scalp.
    Journal of cosmetic dermatology, 2016, Volume: 15, Issue:4

    Topics: Adult; Aged; Anti-Bacterial Agents; Bacteria; Dermatitis, Seborrheic; DNA, Bacterial; DNA, Fungal; E

2016
Efficacy and safety of superficial cryotherapy for alopecia areata: A retrospective, comprehensive review of 353 cases over 22 years.
    The Journal of dermatology, 2017, Volume: 44, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alopecia Areata; Child; Child, Preschool; Cryotherapy; F

2017
Pruritic papules on the scalp and arms.
    Cutis, 2016, Volume: 98, Issue:4

    Topics: Arm; Hair Follicle; Humans; Male; Middle Aged; Mycosis Fungoides; Pruritus; Scalp; Skin Neoplasms

2016
The itchy scalp.
    The British journal of dermatology, 2017, Volume: 176, Issue:1

    Topics: Humans; Pruritus; Scalp; Scalp Dermatoses

2017
Frontal fibrosing alopecia: a clinical review of 36 patients.
    The British journal of dermatology, 2010, Volume: 163, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Alopecia; Anti-Bacterial Agents; Cohort Studies; Dermatologic Agents

2010
Aberrant C nerve fibre function of the healthy scalp.
    The British journal of dermatology, 2012, Volume: 167, Issue:3

    Topics: Adult; Female; Hot Temperature; Humans; Male; Middle Aged; Nerve Fibers, Unmyelinated; Pain; Pain Th

2012
A pediculid case: autosensitization dermatitis caused by pediculosis capitis.
    Turkiye parazitolojii dergisi, 2012, Volume: 36, Issue:3

    Topics: Aged; Animals; Dermatitis; Exanthema; Female; Hair; Humans; Lice Infestations; Lymphatic Diseases; P

2012
Dandruff: a condition characterized by decreased levels of intercellular lipids in scalp stratum corneum and impaired barrier function.
    Archives of dermatological research, 2002, Volume: 294, Issue:5

    Topics: Administration, Cutaneous; Adult; Case-Control Studies; Cholesterol; Dermatitis, Seborrheic; Epiderm

2002
Sensitivity of human scalp skin to pruritic stimuli investigated by intradermal microdialysis in vivo.
    Journal of the American Academy of Dermatology, 2002, Volume: 47, Issue:2

    Topics: Adult; Forearm; Histamine; Humans; Male; Microdialysis; p-Methoxy-N-methylphenethylamine; Pruritus;

2002
Pseudo-delusory syndrome caused by Limothrips cerealium.
    International journal of dermatology, 2006, Volume: 45, Issue:3

    Topics: Agricultural Workers' Diseases; Animals; Delusions; Diagnostic Errors; Ectoparasitic Infestations; E

2006
Successful treatment of recalcitrant necrotizing eosinophilic folliculitis using indomethacin and cephalexin.
    The Australasian journal of dermatology, 2006, Volume: 47, Issue:4

    Topics: Administration, Oral; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Cephalexin; Di

2006
Pediculid. An unusual -id reaction to pediculosis capitis.
    Dermatologica, 1984, Volume: 168, Issue:4

    Topics: Adult; Child, Preschool; Exanthema; Extremities; Female; Humans; Hypersensitivity; Lice Infestations

1984
Fiber implantation for pattern baldness. Review of complications in forty-one patients.
    Journal of the American Academy of Dermatology, 1981, Volume: 4, Issue:3

    Topics: Acrylates; Adult; Alopecia; Cicatrix; Edema; Female; Foreign-Body Reaction; Hair; Humans; Male; Post

1981
Surgical treatment of fiber-implanted scalps.
    Plastic and reconstructive surgery, 1981, Volume: 67, Issue:4

    Topics: Acrylic Resins; Adult; Humans; Male; Middle Aged; Polyvinyl Chloride; Prostheses and Implants; Pruri

1981
Scalp psoriasis, clinical presentations and therapeutic management.
    Dermatology (Basel, Switzerland), 1998, Volume: 197, Issue:4

    Topics: Administration, Topical; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Child

1998
Pityriasis amiantacea.
    Cutis, 1999, Volume: 63, Issue:3

    Topics: Alopecia; Child; Diagnosis, Differential; Elbow; Female; Humans; Pityriasis; Pruritus; Scalp

1999
[Eosinophilic arteritis of the scalp].
    Annales de dermatologie et de venereologie, 2001, Volume: 128, Issue:4

    Topics: Adult; Arteritis; Biopsy; Diagnosis, Differential; Eosinophilia; Female; Humans; Pruritus; Remission

2001
Diabetes and pruritus of the scalp.
    JAMA, 1977, Apr-11, Volume: 237, Issue:15

    Topics: Diabetes Complications; Humans; Pruritus; Scalp

1977
Forehead rhytidoplasty and brow lifting.
    Plastic and reconstructive surgery, 1976, Volume: 57, Issue:4

    Topics: Alopecia; Dermabrasion; Eyebrows; Face; Female; Hematoma; Humans; Male; Postoperative Complications;

1976